false 0001665988--12-31 2024 Q1 http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization 0001665988 2024-01-01 2024-03-30 0001665988 us-gaap:CommonClassAMember 2024-04-30 xbrli:shares 0001665988 us-gaap:CommonClassBMember 2024-04-30 iso4217:USD 0001665988 2023-01-01 2023-04-01 iso4217:USD xbrli:shares 0001665988 2024-03-30 0001665988 2023-12-31 0001665988 us-gaap:CommonClassAMember 2023-12-31 0001665988 us-gaap:CommonClassAMember 2024-03-30 0001665988 us-gaap:CommonClassBMember 2023-12-31 0001665988 us-gaap:CommonClassBMember 2024-03-30 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001665988 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001665988 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001665988 us-gaap:RetainedEarningsMember 2023-12-31 0001665988 us-gaap:NoncontrollingInterestMember 2023-12-31 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-03-30 0001665988 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-30 0001665988 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-30 0001665988 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-30 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-30 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-30 0001665988 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-30 0001665988 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-30 0001665988 us-gaap:RetainedEarningsMember 2024-03-30 0001665988 us-gaap:NoncontrollingInterestMember 2024-03-30 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001665988 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001665988 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001665988 us-gaap:RetainedEarningsMember 2022-12-31 0001665988 us-gaap:NoncontrollingInterestMember 2022-12-31 0001665988 2022-12-31 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-04-01 0001665988 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-04-01 0001665988 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-04-01 0001665988 us-gaap:RetainedEarningsMember 2023-01-01 2023-04-01 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-04-01 0001665988 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-04-01 0001665988 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-04-01 0001665988 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 0001665988 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 0001665988 us-gaap:RetainedEarningsMember 2023-04-01 0001665988 us-gaap:NoncontrollingInterestMember 2023-04-01 0001665988 2023-04-01 0001665988 bvs:BVLLCMember 2024-03-30 bvs:employee 0001665988 us-gaap:CustomerConcentrationRiskMember bvs:CustomerOneMember us-gaap:AccountsReceivableMember 2024-01-01 2024-03-30 xbrli:pure 0001665988 us-gaap:CustomerConcentrationRiskMember bvs:CustomerOneMember us-gaap:AccountsReceivableMember 2023-01-01 2023-12-31 0001665988 bvs:WoundBusinessMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-05-22 0001665988 bvs:WoundBusinessMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-05-22 2023-05-22 0001665988 2023-05-22 2023-05-22 0001665988 bvs:WoundBusinessMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-01-01 2023-04-01 0001665988 bvs:CartiHealLtdMember 2022-07-12 0001665988 bvs:DeferredConsiderationMember bvs:CartiHealLtdMember 2023-02-27 0001665988 bvs:SalesMilestoneMember bvs:CartiHealLtdMember 2023-02-27 0001665988 bvs:CartiHealLtdMember us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleMember 2023-02-27 2023-02-27 0001665988 bvs:CartiHealLtdMember 2023-02-27 2023-02-27 0001665988 bvs:TermLoanMember 2024-03-30 0001665988 bvs:TermLoanMember 2023-12-31 0001665988 us-gaap:RevolvingCreditFacilityMember 2024-03-30 0001665988 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0001665988 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2019-12-06 0001665988 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-06 0001665988 bvs:TermLoanMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2021-08-29 2021-12-29 0001665988 bvs:TermLoanMember us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2021-10-29 0001665988 us-gaap:SecuredDebtMember bvs:TermLoanFacilityJuly2022Member us-gaap:LineOfCreditMember 2022-07-11 2022-07-11 0001665988 us-gaap:SecuredDebtMember bvs:SecuredOvernightFinancingRateSOFRMember 2022-07-12 2022-07-12 0001665988 us-gaap:SecuredDebtMember us-gaap:BaseRateMember 2022-07-12 2022-07-12 0001665988 us-gaap:SecuredDebtMember bvs:SecuredOvernightFinancingRateSOFRMember 2023-03-31 2023-03-31 0001665988 us-gaap:SecuredDebtMember us-gaap:BaseRateMember 2023-03-31 2023-03-31 0001665988 us-gaap:SecuredDebtMember 2023-03-31 0001665988 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember bvs:TermLoanFacilityJanuary2024Member 2024-03-30 0001665988 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember bvs:TermLoanFacilityJanuary2024Member 2024-01-01 2024-03-30 0001665988 bvs:TermLoanFacilityMarch2023Member us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2023-04-01 0001665988 bvs:TermLoanFacilityMarch2023Member us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2023-01-01 2023-04-01 0001665988 us-gaap:LineOfCreditMember 2024-01-01 2024-01-31 0001665988 us-gaap:LineOfCreditMember 2023-03-01 2023-03-31 0001665988 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember bvs:TermLoanFacilitiesMember 2024-03-30 0001665988 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember bvs:TermLoanFacilitiesMember 2023-04-02 2023-07-01 0001665988 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember bvs:TermLoanFacilitiesMember 2024-01-01 2024-03-30 0001665988 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember bvs:TermLoanFacilitiesMember 2023-01-01 2023-04-01 0001665988 us-gaap:FairValueInputsLevel2Member bvs:TermLoanMember 2024-03-30 0001665988 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-06 2019-12-06 0001665988 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001665988 us-gaap:RevolvingCreditFacilityMember srt:ScenarioForecastMember 2024-06-30 2024-06-30 0001665988 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2024-03-30 0001665988 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2019-12-06 0001665988 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2024-03-30 bvs:letter_of_credit 0001665988 us-gaap:BridgeLoanMember us-gaap:LineOfCreditMember 2019-12-06 2019-12-06 0001665988 us-gaap:FairValueMeasurementsRecurringMember bvs:BionessIncMember 2024-03-30 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member bvs:BionessIncMember 2024-03-30 0001665988 us-gaap:FairValueMeasurementsRecurringMember bvs:BionessIncMember 2023-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member bvs:BionessIncMember 2023-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-03-30 0001665988 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001665988 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001665988 srt:MinimumMember us-gaap:ValuationTechniqueDiscountedCashFlowMember us-gaap:MeasurementInputDiscountRateMember us-gaap:FairValueInputsLevel3Member bvs:BionessIncMember 2024-03-30 0001665988 srt:MaximumMember us-gaap:ValuationTechniqueDiscountedCashFlowMember us-gaap:MeasurementInputDiscountRateMember us-gaap:FairValueInputsLevel3Member bvs:BionessIncMember 2024-03-30 0001665988 bvs:BionessIncMember 2024-01-01 2024-03-30 0001665988 bvs:BionessIncMember 2023-01-01 2023-04-01 0001665988 us-gaap:CommonClassAMember bvs:A2021PlanMember 2024-03-30 0001665988 us-gaap:CommonClassAMember bvs:A2023RetentionEquityAwardPlanMember 2024-03-30 0001665988 bvs:A2021And2023PlanMember 2023-01-01 2023-04-01 0001665988 bvs:A2021PlanMember 2024-01-01 2024-03-30 0001665988 bvs:A2021PlanMember 2023-01-01 2023-04-01 0001665988 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-30 0001665988 us-gaap:RestrictedStockUnitsRSUMember srt:MaximumMember 2024-01-01 2024-03-30 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2024-03-30 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-30 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001665988 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-30 0001665988 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2024-01-01 2024-03-30 0001665988 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-30 0001665988 us-gaap:EmployeeStockMember 2024-03-30 0001665988 us-gaap:EmployeeStockMember 2024-01-01 2024-03-30 0001665988 us-gaap:EmployeeStockMember 2023-01-01 2023-04-01 0001665988 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-02-16 2021-02-16 0001665988 us-gaap:CommonClassAMember 2021-02-16 0001665988 us-gaap:CommonClassBMember 2021-02-16 0001665988 2021-02-16 0001665988 bvs:BVLLCMember us-gaap:CommonClassAMember 2021-02-16 2021-02-16 0001665988 us-gaap:CommonClassAMember 2024-01-01 2024-03-30 bvs:vote 0001665988 bvs:BVLLCMember 2024-03-30 0001665988 bvs:BVLLCMember 2024-01-01 2024-03-30 0001665988 bvs:BVLLCMember 2023-12-31 0001665988 bvs:BVLLCMember 2023-01-01 2023-12-31 0001665988 bvs:ContinuingLLCOwnerMember bvs:BVLLCMember 2024-03-30 0001665988 bvs:ContinuingLLCOwnerMember bvs:BVLLCMember 2024-01-01 2024-03-30 0001665988 bvs:ContinuingLLCOwnerMember bvs:BVLLCMember 2023-12-31 0001665988 bvs:ContinuingLLCOwnerMember bvs:BVLLCMember 2023-01-01 2023-12-31 0001665988 bvs:BioventusAndContinuingLLCOwnerMember bvs:BVLLCMember 2024-03-30 0001665988 bvs:BioventusAndContinuingLLCOwnerMember bvs:BVLLCMember 2024-01-01 2024-03-30 0001665988 bvs:BioventusAndContinuingLLCOwnerMember bvs:BVLLCMember 2023-12-31 0001665988 bvs:BioventusAndContinuingLLCOwnerMember bvs:BVLLCMember 2023-01-01 2023-12-31 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2024-01-01 2024-03-30 0001665988 bvs:LimitedLiabilityCompanyInterestsMember 2023-01-01 2023-04-01 0001665988 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-30 0001665988 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-04-01 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-30 0001665988 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-04-01 0001665988 srt:MinimumMember 2024-03-30 0001665988 srt:MaximumMember 2024-03-30 0001665988 bvs:HAProductMember 2021-11-10 2021-11-10 0001665988 bvs:HAProductMember 2022-01-01 2022-12-31 0001665988 bvs:HAProductMember 2023-03-08 2023-03-08 0001665988 bvs:HAProductMember 2024-01-31 2024-01-31 0001665988 bvs:HarborMember 2019-08-23 2019-08-23 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2024-01-01 2024-03-30 0001665988 bvs:SupplierOfSingleInjectionOAProductMember 2023-01-01 2023-04-01 0001665988 bvs:ThreeInjectionOAProductMember 2016-02-09 2016-02-09 0001665988 bvs:HarborMember 2020-12-22 2020-12-22 0001665988 country:US 2023-01-01 2023-04-01 0001665988 us-gaap:NonUsMember 2023-01-01 2023-04-01 0001665988 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember bvs:CustomerOneMember 2024-01-01 2024-03-30 0001665988 bvs:PainTreatmentsMember country:US 2024-01-01 2024-03-30 0001665988 bvs:PainTreatmentsMember country:US 2023-01-01 2023-04-01 0001665988 bvs:RestorativeTherapiesMember country:US 2024-01-01 2024-03-30 0001665988 bvs:RestorativeTherapiesMember country:US 2023-01-01 2023-04-01 0001665988 bvs:SurgicalSolutionsMember country:US 2024-01-01 2024-03-30 0001665988 bvs:SurgicalSolutionsMember country:US 2023-01-01 2023-04-01 0001665988 country:US 2024-01-01 2024-03-30 0001665988 bvs:PainTreatmentsMember us-gaap:NonUsMember 2024-01-01 2024-03-30 0001665988 bvs:PainTreatmentsMember us-gaap:NonUsMember 2023-01-01 2023-04-01 0001665988 bvs:RestorativeTherapiesMember us-gaap:NonUsMember 2024-01-01 2024-03-30 0001665988 bvs:RestorativeTherapiesMember us-gaap:NonUsMember 2023-01-01 2023-04-01 0001665988 bvs:SurgicalSolutionsMember us-gaap:NonUsMember 2024-01-01 2024-03-30 0001665988 bvs:SurgicalSolutionsMember us-gaap:NonUsMember 2023-01-01 2023-04-01 0001665988 us-gaap:NonUsMember 2024-01-01 2024-03-30 bvs:segment 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-30 0001665988 bvs:USSegmentMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-04-01 0001665988 us-gaap:OperatingSegmentsMember bvs:InternationalSegmentMember 2024-01-01 2024-03-30 0001665988 us-gaap:OperatingSegmentsMember bvs:InternationalSegmentMember 2023-01-01 2023-04-01 0001665988 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-03-30 0001665988 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-04-01 0001665988 bvs:CartiHealMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-01 2024-03-30 0001665988 bvs:CartiHealMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-01-01 2023-04-01 0001665988 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2023-04-01 0001665988 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-03-30
‘ m`

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 10-Q
________________
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 30, 2024
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________
Commission File Number: 001-37844
BIOVENTUS INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware |  | 81-0980861
(State or Other Jurisdiction of Incorporation or Organization) |  | (I.R.S. Employer Identification No.)
4721 Emperor Boulevard, Suite 100 |  |
Durham, North Carolina |  | 27703
(Address of Principal Executive Offices) |  | (Zip Code)

(919) 474-6700
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Class A Common Stock, $0.001 par value per share | BVS | The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☐ |  | Accelerated filer | ☒
Non-accelerated filer | ☐ |  | Smaller reporting company | ☒
|  |  | Emerging Growth Company | ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of April 30, 2024, there were 63,827,617 shares of Class A common stock outstanding and 15,786,737 shares of Class B common stock outstanding.

BIOVENTUS INC.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Item 1. | Financial Statements (Unaudited) |
| Consolidated Condensed Statements of Operations and Comprehensive Loss for the three months ended March 30, 2024 and April 1, 2023 | 1
| Consolidated Condensed Balance Sheets as of March 30, 2024 and December 31, 2023 | 2
| Consolidated Condensed Statements of Changes in Stockholders’ Equity for the three months ended March 30, 2024 and April 1, 2023 | 3
| Consolidated Condensed Statements of Cash Flows for the three months ended March 30, 2024 and April 1, 2023 | 4
| Notes to the Unaudited Consolidated Condensed Financial Statements | 5
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 20
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 28
Item 4. | Controls and Procedures | 28
PART II. OTHER INFORMATION
Item 1. | Legal Proceedings | 28
Item 1A. | Risk Factors | 29
Item 2. | Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities | 30
Item 3. | Defaults Upon Senior Securities | 30
Item 4. | Mine Safety Disclosures | 30
Item 5. | Other Information | 30
Item 6. | Exhibits | 30
Signature | 32

Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
As used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to "Bioventus," "we," "us," "our," "the Company," and similar references refer to Bioventus Inc. and its consolidated subsidiaries, including Bioventus LLC (“BV LLC”).
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and Section 27A of the Securities Act of 1933, as amended (“Securities Act”), concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements regarding our business strategy, including, without limitation, expectations relating to our integration of Misonix and Bioness, potential acquisitions, expected expansion of our pipeline and research and development investment, cost savings initiatives, new therapy launches, expected timelines for clinical trial results and other development milestones, expected contractual obligations and capital expenditures, recent dispositions of non-core assets, our domestic and international operations and expected financial performance and condition, and impacts of the COVID-19 pandemic, inflation and ongoing conflicts in Israel. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Important factors that may cause actual results to differ materially from current expectations include, among other things: the risk that previously identified material weaknesses or new material weaknesses could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner; we might not be able to continue to fund our operations for at least the next twelve months as a going concern; we might not meet certain of our debt covenants under our Credit Agreement and might be required to repay our indebtedness; risks associated with the disposition of our Wound Business and expected impacts on our business; restrictions on operations and other costs associated with our indebtedness; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; we maintain cash at financial institutions, often in balance that exceed federally insured limits; we are subject to securities class action litigation and may be subject to similar or other litigation in the future, which will require significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes; our ability to maintain our competitive position depends on our ability to attract, retain and motivate our senior management team and highly qualified personnel; we are highly dependent on a limited number of products; our long-term growth depends on our ability to develop, acquire and commercialize new products, line extensions or expanded indications; we may be unable to successfully commercialize newly developed or acquired products or therapies in the United States; demand for our existing portfolio of products and any new products, line extensions or expanded indications depends on the continued and future acceptance of our products by physicians, patients, third-party payers and others in the medical community; the proposed down classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration (“FDA”) could increase future competition for bone growth stimulators and otherwise adversely affect the Company’s sales of Exogen; failure to achieve and maintain adequate levels of coverage and/or reimbursement for our products or future products, the procedures using our products, such as our hyaluronic acid (“HA”) viscosupplements, or future products we may seek to commercialize; pricing pressure and other competitive factors; governments outside the United States might not provide coverage or reimbursement of our products; we compete and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than we do; if our HA products are reclassified from medical devices to drugs in the United States by the FDA, it could negatively impact our ability to market these products and may require that we conduct costly additional clinical studies to support current or future indications for use of those products; our failure to properly manage our anticipated growth and strengthen our brands; risks related to product liability claims; fluctuations in demand for our products; issues relating to the supply of our products, potential supply chain disruptions, and the increased cost of parts and components used to manufacture our products due to inflation; our reliance on a

Table of Contents
limited number of third-party manufacturers to manufacture certain of our products; if our facilities are damaged or become inoperable, we will be unable to continue to research, develop and manufacture certain of our products; economic, political, regulatory and other risks related to international sales, manufacturing and operations; failure to maintain contractual relationships; security breaches, unauthorized disclosure of information, denial of service attacks or the perception that confidential information in our possession is not secure; failure of key information technology and communications systems, process or sites; risks related to our debt and future capital needs; failure to comply with extensive governmental regulation relevant to us and our products; we may be subject to enforcement action if we engage in improper claims submission practices and resulting audits or denials of our claims by government agencies could reduce our net sales or profits; the FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required regulatory clearances and approvals could prevent us from commercializing our products; if clinical studies of our future product candidates do not produce results necessary to support regulatory clearance or approval in the United States or elsewhere, we will be unable to expand the indications for or commercialize these products; legislative or regulatory reforms; our business may continue to experience adverse impacts as a result of the COVID-19 pandemic or similar epidemics; risks related to intellectual property matters; and other important factors described in Part I. Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023, as may be further updated from time to time in our other filings with the SEC. You are urged to consider these factors carefully in evaluating these forward-looking statements. These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
Bioventus Inc.
Consolidated Condensed Statements of Operations and Comprehensive Loss
Three Months Ended March 30, 2024 and April 1, 2023
(Amounts in thousands, except share amounts)
(Unaudited)

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Net sales | $ | 129,457 |  |  | $ | 119,059 |
Cost of sales (including depreciation and amortization of $10,025 and $14,339, respectively) | 41,077 |  |  | 45,140 |
Gross profit | 88,380 |  |  | 73,919 |
Selling, general and administrative expense | 78,406 |  |  | 80,858 |
Research and development expense | 2,597 |  |  | 3,771 |
Restructuring costs | — |  |  | 317 |
Change in fair value of contingent consideration | 295 |  |  | 287 |
Depreciation and amortization | 1,755 |  |  | 2,129 |
Impairments of assets | — |  |  | 78,615 |
Operating income (loss) | 5,327 |  |  | (92,058) |
Interest expense, net | 10,339 |  |  | 9,694 |
Other expense (income) | 63 |  |  | (1,588) |
Other expense | 10,402 |  |  | 8,106 |
Loss before income taxes | (5,075) |  |  | (100,164) |
Income tax expense (benefit), net | 907 |  |  | (146) |
Net loss from continuing operations | (5,982) |  |  | (100,018) |
Loss from discontinued operations, net of tax | — |  |  | (74,429) |
Net loss | (5,982) |  |  | (174,447) |
Loss attributable to noncontrolling interest - continuing operations | 1,412 |  |  | 20,360 |
Loss attributable to noncontrolling interest - discontinued operations | — |  |  | 14,937 |
Net loss attributable to Bioventus Inc. | $ | (4,570) |  |  | $ | (139,150) |
Net loss | $ | (5,982) |  |  | $ | (174,447) |
Other comprehensive (loss) income, net of tax |  |  |
Change in foreign currency translation adjustments | (585) |  |  | 657 |
Comprehensive loss | (6,567) |  |  | (173,790) |
Comprehensive loss attributable to noncontrolling interest - continuing operations | 1,528 |  |  | 20,226 |
Comprehensive loss attributable to noncontrolling interest - discontinued operations | — |  |  | 14,937 |
Comprehensive loss attributable to Bioventus Inc. | $ | (5,039) |  |  | $ | (138,627) |
Loss per share of Class A common stock from continuing operations, basic and diluted: | $ | (0.07) |  |  | $ | (1.28) |
Loss per share of Class A common stock from discontinued operations, basic and diluted: | — |  |  | (0.96) |
Loss per share of Class A common stock, basic and diluted | $ | (0.07) |  |  | $ | (2.24) |
Weighted-average shares of Class A common stock outstanding, basic and diluted: | 63,380,187 |  | 62,124,752

The accompanying notes are an integral part of these consolidated financial statements.
1

Table of Contents
Bioventus Inc.
Consolidated Condensed Balance Sheets as of March 30, 2024 and December 31, 2023
(Amounts in thousands, except share amounts)
(Unaudited)

| March 30, 2024 |  | December 31, 2023
Assets |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 25,173 |  |  | $ | 36,964 |
Accounts receivable, net | 125,541 |  |  | 122,789 |
Inventory | 97,005 |  |  | 91,333 |
Prepaid and other current assets | 18,184 |  |  | 16,913 |
Total current assets | 265,903 |  |  | 267,999 |
Property and equipment, net | 34,532 |  |  | 36,605 |
Goodwill | 7,462 |  |  | 7,462 |
Intangible assets, net | 470,668 |  |  | 482,350 |
Operating lease assets | 12,462 |  |  | 13,353 |
Investment and other assets | 3,211 |  |  | 3,141 |
Total assets | $ | 794,238 |  |  | $ | 810,910 |
Liabilities and Stockholders' Equity |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 19,099 |  |  | $ | 23,038 |
Accrued liabilities | 113,605 |  |  | 119,795 |
Current portion of long-term debt | 35,811 |  |  | 27,848 |
Other current liabilities | 4,806 |  |  | 4,816 |
Total current liabilities | 173,321 |  |  | 175,497 |
Long-term debt, less current portion | 355,430 |  |  | 366,998 |
Deferred income taxes | 1,294 |  |  | 1,213 |
Contingent consideration | 18,445 |  |  | 18,150 |
Other long-term liabilities | 28,316 |  |  | 27,934 |
Total liabilities | 576,806 |  |  | 589,792 |
Commitments and contingencies (Note 11) |  |  |
Stockholders’ Equity |  |  |
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued |  |  |
Class A common stock, $0.001 par value, 250,000,000 shares authorized as of March 30, 2024 and December 31, 2023, 63,672,170 and 63,267,436 shares issued and outstanding as of March 30, 2024 and December 31, 2023, respectively | 64 |  |  | 63 |
Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of March 30, 2024 and December 31, 2023 | 16 |  |  | 16 |
Additional paid-in capital | 496,977 |  |  | 494,254 |
Accumulated deficit | (326,106) |  |  | (321,536) |
Accumulated other comprehensive income | 325 |  |  | 794 |
Total stockholders’ equity attributable to Bioventus Inc. | 171,276 |  |  | 173,591 |
Noncontrolling interest | 46,156 |  |  | 47,527 |
Total stockholders’ equity | 217,432 |  |  | 221,118 |
Total liabilities and stockholders’ equity | $ | 794,238 |  |  | $ | 810,910 |

The accompanying notes are an integral part of these consolidated financial statements.
2

Table of Contents
Bioventus Inc.
Consolidated Condensed Statements of Changes in Stockholders’ Equity
Three Months Ended March 30, 2024 and April 1, 2023
(Amounts in thousands, except share amounts)
(Unaudited)

Three Months Ended March 30, 2024
| Class A Common Stock |  | Class B Common Stock |  |  |  |  |  |  |  |  |  |
| Shares | Amount |  | Shares | Amount |  | Additional Paid-in Capital |  | Accumulated other comprehensive income (loss) |  | Accumulated Deficit |  | Non- controlling interest |  | Total Stockholders' equity
Balance at December 31, 2023 | 63,267,436 |  | $ | 63 |  |  | 15,786,737 |  | $ | 16 |  |  | $ | 494,254 |  |  | $ | 794 |  |  | $ | (321,536) |  |  | $ | 47,527 |  |  | $ | 221,118 |
Issuance of Class A common stock for equity plans | 404,734 |  | 1 |  |  | — |  | — |  |  | 289 |  |  | — |  |  | — |  |  | — |  |  | 290 |
Net loss | — |  | — |  |  | — |  | — |  |  | — |  |  | — |  |  | (4,570) |  |  | (1,412) |  |  | (5,982) |
Change in noncontrolling interest allocation | — |  | — |  |  | — |  | — |  |  | 319 |  |  | — |  |  | — |  |  | (319) |  |  | — |
Equity based compensation | — |  | — |  |  | — |  | — |  |  | 2,115 |  |  | — |  |  | — |  |  | 476 |  |  | 2,591 |
Translation adjustment | — |  | — |  |  | — |  | — |  |  | — |  |  | (469) |  |  | — |  |  | (116) |  |  | (585) |
Balance at March 30, 2024 | 63,672,170 |  | $ | 64 |  |  | 15,786,737 |  | $ | 16 |  |  | $ | 496,977 |  |  | $ | 325 |  |  | $ | (326,106) |  |  | $ | 46,156 |  |  | $ | 217,432 |

Three Months Ended April 1, 2023
| Class A Common Stock |  | Class B Common Stock |  |  |  |  |  |  |  |  |  |
| Shares | Amount |  | Shares | Amount |  | Additional Paid-in Capital |  | Accumulated other comprehensive (loss) income |  | Accumulated Deficit |  | Non- controlling interest |  | Total Stockholders' equity
Balance at December 31, 2022 | 62,063,014 |  | $ | 62 |  |  | 15,786,737 |  | $ | 16 |  |  | $ | 490,576 |  |  | $ | (110) |  |  | $ | (165,306) |  |  | $ | 86,984 |  |  | $ | 412,222 |
Issuance of Class A common stock for equity plans | 444,903 |  | 1 |  |  | — |  | — |  |  | 360 |  |  | — |  |  | — |  |  | (277) |  |  | 84 |
Net loss | — |  | — |  |  | — |  | — |  |  | — |  |  | — |  |  | (139,150) |  |  | (35,297) |  |  | (174,447) |
Equity based compensation | — |  | — |  |  | — |  | — |  |  | 1,539 |  |  | — |  |  | — |  |  | 307 |  |  | 1,846 |
Translation adjustment | — |  | — |  |  | — |  | — |  |  | — |  |  | 523 |  |  | — |  |  | 134 |  |  | 657 |
Balance at April 1, 2023 | 62,507,917 |  | $ | 63 |  |  | 15,786,737 |  | $ | 16 |  |  | $ | 492,475 |  |  | $ | 413 |  |  | $ | (304,456) |  |  | $ | 51,851 |  |  | $ | 240,362 |

The accompanying notes are an integral part of these consolidated financial statements.
3

Table of Contents
Bioventus Inc.
Consolidated Condensed Statements of Cash Flows
Three Months Ended March 30, 2024 and April 1, 2023
(Amounts in thousands)
(Unaudited)

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Operating activities: |  |  |
Net loss | $ | (5,982) |  |  | $ | (174,447) |
Less: Loss from discontinued operations, net of tax | — |  |  | (74,429) |
Loss from continuing operations | (5,982) |  |  | (100,018) |
Adjustments to reconcile net loss to net cash from operating activities: |  |  |
Depreciation and amortization | 11,785 |  |  | 16,473 |
(Benefit) provision for expected credit losses | (976) |  |  | 1,079 |
Equity-based compensation | 2,591 |  |  | 1,846 |
Change in fair value of contingent consideration | 295 |  |  | 287 |
Deferred income taxes | 81 |  |  | (2,664) |
Impairment of assets | — |  |  | 78,615 |
Unrealized loss on foreign currency fluctuations | 377 |  |  | 747 |
Other, net | 581 |  |  | 224 |
Changes in operating assets and liabilities: |  |  |
Accounts receivable | (1,958) |  |  | 13,162 |
Inventories | (4,070) |  |  | (5,294) |
Accounts payable and accrued expenses | (7,332) |  |  | 2,331 |
Other current and noncurrent assets and liabilities | (1,397) |  |  | (2,129) |
Net cash from operating activities - continuing operations | (6,005) |  |  | 4,659 |
Net cash from operating activities - discontinued operations | — |  |  | (2,169) |
Net cash from operating activities | (6,005) |  |  | 2,490 |
Investing activities: |  |  |
Purchase of property and equipment | (291) |  |  | (3,560) |
Investments and acquisition of distribution rights | (709) |  |  | — |
Net cash from investing activities - continuing operations | (1,000) |  |  | (3,560) |
Net cash from investing activities - discontinued operations | — |  |  | (11,506) |
Net cash from investing activities | (1,000) |  |  | (15,066) |
Financing activities: |  |  |
Proceeds from issuance of Class A common stock | 177 |  |  | 84 |
Borrowing on revolver | — |  |  | 49,000 |
Payment on revolver | — |  |  | (20,000) |
Debt refinancing costs | (1,180) |  |  | (1,668) |
Payments on long-term debt | (3,056) |  |  | — |
Other, net | (183) |  |  | (36) |
Net cash from financing activities | (4,242) |  |  | 27,380 |
Effect of exchange rate changes on cash | (544) |  |  | 461 |
Net change in cash, cash equivalents and restricted cash | (11,791) |  |  | 15,265 |
Cash, cash equivalents and restricted cash at the beginning of the period | 36,964 |  |  | 31,837 |
Cash, cash equivalents and restricted cash at the end of the period | $ | 25,173 |  |  | $ | 47,102 |
Supplemental disclosure of noncash investing and financing activities |  |  |
Accounts payable for purchase of property, plant and equipment | $ | 218 |  |  | $ | — |

The accompanying notes are an integral part of these consolidated financial statements.
4

Table of Contents
Bioventus Inc.
Notes to the unaudited consolidated condensed financial statements
(Amounts in thousands, except unit and share amounts)
1. Organization
The Company
Bioventus Inc. (together with its subsidiaries, the “Company”) was formed as a Delaware corporation for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Bioventus LLC and its subsidiaries (“BV LLC”). Bioventus Inc. functions as a holding company with no direct operations, material assets or liabilities other than the equity interest in BV LLC. BV LLC is a limited liability company formed under the laws of the state of Delaware on November 23, 2011 and operates as a partnership. BV LLC commenced operations in May 2012.
On February 16, 2021, the Company completed its initial public offering (“IPO”), which was conducted through what is commonly referred to as an umbrella partnership C Corporation (“UP-C”) structure. The Company has majority interest, sole voting interest and controls the management of BV LLC. As a result, the Company consolidates the financial results of BV LLC and reports a noncontrolling interest representing the interest of BV LLC held by its continuing LLC owner.
The Company is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing processes. The Company is headquartered in Durham, North Carolina and has approximately 995 employees.
Interim periods
The Company reports quarterly interim periods on a 13-week basis within a standard calendar year. Each annual reporting period begins on January 1 and ends on December 31. Each quarter ends on the Saturday closest to calendar quarter-end, with the exception of the fourth quarter, which ends on December 31. The 13-week quarterly periods for fiscal year 2024 end on March 30, June 29 and September 28. Comparable periods for 2023 ended on April 1, July 1 and September 30. The fourth and first quarters may vary in length depending on the calendar year.
Unaudited interim financial information
The accompanying unaudited consolidated condensed financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments, and the adjustments discussed in Note 1. Organization) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements of the Company, but does not include all the disclosures required by U.S. GAAP.
Reclassifications
Certain prior period amounts have been reclassified to conform to current period presentation. In 2024, the Company reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems (“SonicOne”) from the Restorative Therapies to the Surgical Solutions business. The reclassification of SonicOne activity effected prior presentation of disaggregated revenue by business, refer to Note 12. Revenue recognition for further details. The reclassification had no effect on previously reported total revenues, net loss, other comprehensive loss, stockholders’ equity or cash flows. Unless otherwise noted, all financial information in the unaudited consolidated condensed financial statements reflects the Company’s results from continuing operations.
5

Table of Contents
Use of estimates
The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. On an ongoing basis, management evaluates these estimates, including those related to contractual allowances and sales incentives, allowance for credit losses, inventory reserves, goodwill and intangible assets impairment, valuation of assets and liabilities assumed in acquisitions, useful lives of long lived assets, fair value measurements, litigation and contingent liabilities, income taxes, and equity-based compensation. Management bases its estimates on historical experience, future expectations and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.
Emerging Growth Company and Smaller Reporting Company Status
The Company is an “emerging growth company,” pursuant to the provisions of the Jumpstart Our Business Startups Act (the “JOBS ACT”). An emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has chosen to “opt out” of such extended transition periods, and as a result, the Company plans to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that the decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.
The Company is also considered a “smaller reporting company,” as defined by Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”), which was determined as of the last day of the Company’s second fiscal quarter of 2023. The Company will continue to be categorized as a smaller reporting company-accelerated filer until the Company’s public float reaches a certain threshold. The Company may rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Recent accounting pronouncements
In addition to being a smaller reporting and an emerging growth company, the Company also is an accelerated filer under SEC rules and regulations. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than when smaller reporting companies and emerging growth companies who are not accelerated filers are required to adopt.
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2023-09 (“ASU 2023-09”), Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating this ASU to determine its impact on the Company's disclosures.
In November 2023, the FASB issued Accounting Standards Update 2023-07 (“ASU 2023-07”), Segment Reporting, which improves reportable segment disclosure requirements. ASU 2023-07 primarily enhances disclosures about significant segment expenses by requiring that a public entity disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of segment profit or loss. This ASU also (i) requires that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment, and a description of its composition; (ii) requires that all annual disclosures are provided in the interim periods; (iii) clarifies that if the CODM uses more than one measure of profitability in assessing segment performance and deciding how to allocate resources, that one or more of those measures may be reported; (iv) requires disclosure of the title and position of the CODM and a description of how the reported measures are used by the CODM in assessing segment performance and in deciding how to allocate resources; (v) requires that an entity with a single segment provide all new required disclosures. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and requires retrospective application. Early adoption is permitted. The amendments under ASU 2023-07 relate to financial disclosures and its adoption will not have an impact on the Company’s results of operations, financial position or cash flows. The Company will adopt ASU 2023-07 for the annual reporting period ending December 31, 2024 and for interim reporting periods thereafter.
6

Table of Contents
2. Balance sheet information
Accounts receivable, net
Accounts receivable, net are amounts billed and currently due from customers. The Company records the amounts due net of allowance for credit losses. Collection of the consideration that the Company expects to receive typically occurs within 30 to 90 days of billing. The Company applies the practical expedient for contracts with payment terms of one year or less which does not consider the effects of the time value of money. Occasionally, the Company enters into payment agreements with patients that allow payment terms beyond one year. In those cases, the financing component is not deemed significant to the contract.
Accounts receivable, net of allowances, consisted of the following as of:

| March 30, 2024 |  | December 31, 2023
Accounts receivable | $ | 128,670 |  |  | $ | 127,008 |
Less: Allowance for credit losses | (3,129) |  |  | (4,219) |
| $ | 125,541 |  |  | $ | 122,789 |

Due to the short-term nature of the Company’s receivables, the estimate of expected credit losses is based on aging of the account receivable balances. The allowance is adjusted on a specific identification basis for certain accounts as well as pooling of accounts with similar characteristics. The Company has a diverse customer base with no single customer representing ten percent or more of sales. The Company has one customer representing approximately 18.7% and 16.0% of the accounts receivable balance as of March 30, 2024 and December 31, 2023, respectively. Historically, the Company’s reserves have been adequate to cover credit losses.
Changes in credit losses were as follows:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Beginning balance | $ | (4,219) |  |  | $ | (7,022) |
Benefit (provision) for expected credit losses | 976 |  |  | (1,079) |
Write-offs | 223 |  |  | 286 |
Recoveries | (109) |  |  | (484) |
Disposition | — |  |  | 898 |
Ending balance | $ | (3,129) |  |  | $ | (7,401) |

Inventory
Inventory consisted of the following as of:

| March 30, 2024 |  | December 31, 2023
Raw materials and supplies | $ | 25,690 |  |  | $ | 21,062 |
Finished goods | 71,315 |  |  | 70,271 |
| 97,005 |  |  | 91,333 |

Accrued liabilities
Accrued liabilities consisted of the following as of:

| March 30, 2024 |  | December 31, 2023
Gross-to-net deductions | $ | 63,891 |  |  | $ | 59,592 |
Bonus and commission | 13,869 |  |  | 19,437 |
Compensation and benefits | 6,341 |  |  | 9,709 |
Accrued interest | 6,451 |  |  | 6,606 |
Income and other taxes | 5,017 |  |  | 4,749 |
Other liabilities | 18,036 |  |  | 19,702 |
| $ | 113,605 |  |  | $ | 119,795 |

7

Table of Contents
3. Acquisitions and divestitures
Wound Business
On May 22, 2023, the Company closed the sale of certain assets within its Wound Business, including the TheraSkin and TheraGenesis products (collectively, the “Wound Business” or the “Disposal Group”), for potential consideration of $84,675, including $34,675 at closing, $5,000 deferred for 18 months and up to $45,000 in potential earn-out payments (“Earn-out Payments”), which are based on the achievement of certain revenue thresholds by the purchaser of the Wound Business for sales of the TheraSkin and TheraGenesis products during the 2024, 2025 and 2026 fiscal years.
The Company incurred $3,880 in transactional fees resulting from the sale of the Wound Business. The Company used the proceeds from the sale of its Wound Business to prepay $30,000 of long-term debt obligations. Refer to Note 4. Financial Instruments for further details regarding the Company’s outstanding long-term debt obligations.
The Company evaluated the Wound Business for impairment prior to its sale and recorded a $78,615 impairment within the consolidated condensed statements of operations and comprehensive loss during the three months ended April 1, 2023 as a result of this evaluation to reduce the intangible assets of the Disposal Group to reflect their respective fair values less any costs to sell. The fair value of the Disposal Group’s intangibles was determined based on the consideration received for the Wound Business.
CartiHeal (2009) Ltd.
On July 12, 2022, the Company completed the acquisition of 100% of the remaining shares in CartiHeal (2009) Ltd. (“CartiHeal”), a developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. On February 27, 2023, the Company entered into a settlement agreement (the “Settlement Agreement”) with Elron Ventures Ltd. (“Elron”), as representative of CartiHeal’s former securityholders (the “Former Securityholders”). Pursuant to the Settlement Agreement, Elron, on behalf of the Former Securityholders, agreed to forbear from initiating any legal action or proceedings related to non-payment of any obligations including deferred purchase price and contingent consideration totaling $215,000 and $135,000, respectively, under the Company’s previous agreements to purchase CartiHeal from the Former Securityholders.
Pursuant to the Settlement Agreement, the Company also transferred 100% of its shares in CartiHeal to a trustee (the “Trustee”) for the benefit of the Former Securityholders and made a one-time non-refundable payment of $10,150 to Elron to be used for purposes set forth in the Settlement Agreement. Given that upon execution of the Settlement Agreement, the Company had no ownership interest or voting rights in CartiHeal, the Company concluded that it had ceased to control CartiHeal for accounting purposes, and therefore, deconsolidated CartiHeal effective February 27, 2023. CartiHeal was part of the Company’s international reporting segment and the Company treated the deconsolidation of CartiHeal as a discontinued operation. The loss on disposal was $60,639 and was recorded within discontinued operations, net of tax within the consolidated condensed statements of operations and comprehensive loss for the three months ended April 1, 2023. Refer to Note 14. Discontinued operation s for further information regarding the impact of CartiHeal on the Company’s consolidated condensed financial statements for the three months ended April 1, 2023.
4. Financial instruments
Long-term debt consisted of the following as of:

| March 30, 2024 |  | December 31, 2023
Amended Term Loan due October 2026 (9.82% at March 30, 2024) | $ | 379,392 |  |  | $ | 382,448 |
Revolver due October 2025 (9.82% at March 30, 2024) | 15,000 |  |  | 15,000 |
Less: |  |  |
Current portion of long-term debt | (35,811) |  |  | (27,848) |
Unamortized debt issuance cost | (1,616) |  |  | (917) |
Unamortized discount | (1,535) |  |  | (1,685) |
| $ | 355,430 |  |  | $ | 366,998 |

8

Table of Contents
Amended Term Loan
On December 6, 2019, the Company entered into a Credit and Guaranty Agreement (the “2019 Credit Agreement”) that was comprised of a $200,000 term loan (the “Original Term Loan”) and a $50,000 revolving facility (the “Revolver”). The Company amended the 2019 Credit Agreement on August 29, 2021, and then again on October 29, 2021 in connection with the acquisition of Misonix, Inc., in which the Company prepaid $80,000 on the Original Term Loan. The 2019 Credit Agreement, as amended, subsequent to the prepayment, was comprised of a $360,750 term loan (“Term Loan”) and the Revolver.
On July 11, 2022, the Company further amended the 2019 Credit Agreement in conjunction with the acquisition of CartiHeal (the “CartiHeal Acquisition”). Pursuant to that amendment, an $80,000 term loan facility (the “July 2022 Term Loan” and, together with the Term Loan, the “Term Loan Facilities”) was extended to the Company to be used for: (i) the financing of the CartiHeal Acquisition; (ii) the payment of related fees and expenses; (iii) repayment of the draws made on the Revolver; and (iv) working capital needs and general corporate purposes of the Company, including without limitation for permitted acquisitions.
On March 31, 2023, the Company entered into an additional amendment to the 2019 Credit Agreement to, among other things, modify certain financial covenants, waive covenant noncompliance at December 31, 2022, and to modify interest rates applicable to borrowings under the 2019 Credit Agreement.
On January 18, 2024 (the “Closing Date”), the Company further amended the 2019 Credit Agreement (collectively, with the August 2021, October 2021, July 2022 and March 2023 amendments, the “Amended 2019 Credit Agreement”), to further modify certain financial covenants under the 2019 Credit Agreement. The Company was in compliance as of March 30, 2024 with the financial covenants as stated within the 2019 Credit Agreement.
SOFR loans and base rate loans had a margin of 3.25% and 2.25%, respectively, subsequent to July 11, 2022 and prior to the Closing Date. As of the March 31, 2023 amendment, SOFR loans and base rate loans had a margin of 4.25% and 3.25%, respectively. All obligations under the Amended 2019 Credit Agreement are guaranteed by the Company and certain wholly owned subsidiaries where substantially all the assets of the Company collateralize the obligations.
The Amended 2019 Credit Agreement contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of Bioventus LLC’s equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of assets of Bioventus LLC and its subsidiaries, as well as limitations on making changes to the business and organizational documents of Bioventus LLC and its subsidiaries. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of financial statements of the Company for the fiscal quarter ending October 29, 2025, the Company will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10,000 as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025.
The January 2024 amendment had deferred financing costs of $1,180, of which $325 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $855 was capitalized on the consolidated condensed balance sheets during the three months ended March 30, 2024. The March 2023 amendment had deferred financing costs of $3,661, of which $1,617 was recorded in selling, general and administrative expense within the consolidated condensed statements of operations and comprehensive loss and $2,044 was capitalized on the consolidated condensed balance sheets during the three months ended April 1, 2023. There were no losses on debt refinancing and modification as a result of either the January 2024 or March 2023 amendments.
As of March 30, 2024, $376,241 was outstanding on the Term Loan Facilities, net of original issue discount of $1,535 and deferred financing costs of $1,616. As previously discussed in Note 3. Acquisitions and divestitures, the Company made a prepayment of $30,000 on its Term Loan Facilities with the proceeds from the Wound Business divestiture during the second quarter of 2023. Capitalized deferred fees are amortized to interest expense on a straight-line basis over the term of the Term Loan Facilities, which approximates the effective interest method. Interest expense includes deferred cost amortization of $381 and $223 for the three months ended March 30, 2024 and April 1, 2023, respectively.
The estimated fair value of the Term Loan Facilities was $380,341 as of March 30, 2024. The fair value of these obligations was determined based on the midpoint of the Bloomberg Valuation. This is classified as a Level 2 instruments within the fair value hierarchy.
9

Table of Contents
Revolver and Letters of Credit
The Revolver is a five-year revolving credit facility that includes revolving and swingline loans as well as letters of credit (“LOC”) and, inclusive of all, cannot exceed $45,000 at any one time as the Revolver capacity was reduced at December 31, 2023 in accordance with the 2019 Credit Agreement then in effect. The Revolver credit capacity will be further reduced by $5,000 on June 30, 2024. The Company had $15,000 outstanding borrowings on its Revolver as of March 30, 2024 and December 31, 2023. LOCs are available in an amount not to exceed $7,500. The Company had three LOCs outstanding as of March 30, 2024, leaving approximately $5,700 available. Revolving loans are due at the earlier of termination or maturity. Swingline loans are available as base rate option loans only and must be outstanding for at least five days. Swingline loans are due the fifteenth or last day of a calendar month or maturity, whichever is earlier.
5. Fair value measurements
The process for determining fair value has not changed from that described in the Annual Report on Form 10-K for the year ended December 31, 2023.
There were no assets measured at fair value on a recurring basis and there were no liabilities valued at fair value using Level 1 or Level 2 inputs. The following table provides information for assets and liabilities measured at fair value on a recurring basis using Level 3 inputs:

| March 30, 2024 |  | December 31, 2023
| Total |  |  |  | Level 3 |  | Total |  |  |  | Level 3
Liabilities: |  |  |  |  |  |  |  |  |  |  |
Bioness contingent consideration | $ | 18,445 |  |  |  |  | $ | 18,445 |  |  | $ | 18,150 |  |  |  |  | $ | 18,150 |
Total liabilities: | $ | 18,445 |  |  |  |  | $ | 18,445 |  |  | $ | 18,150 |  |  |  |  | $ | 18,150 |

Contingent consideration
The Company initially values contingent consideration related to business combinations using a probability-weighted calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows for certain milestones. For other milestones, the Company used a variation of the income approach where revenue was simulated in a risk-neutral framework using Geometric Brownian Motion, a stock price behavior model.
Key assumptions used to estimate the fair value of contingent consideration include projected financial information, market data and the probability and timing of achieving the specific targets. After the initial valuation, the Company generally uses its best estimate to measure contingent consideration at each subsequent reporting period using unobservable Level 3 inputs.
Unobservable inputs
A summary of unobservable Level 3 inputs utilized for the above liabilities are as follows:

| Valuation Technique |  | Unobservable inputs |  | Range
Bioness contingent consideration | Discounted cash flow |  | Payment discount rate |  | 6.4% - 6.8%
|  |  | Payment period |  | 2024 - 2025

Significant changes in these assumptions could result in a significantly higher or lower fair value. The contingent consideration reported in the table above resulted from the acquisition of Bioness on March 30, 2021. Contingent consideration is adjusted quarterly based upon the passage of time or the anticipated success or failure of achieving certain milestones. Changes in contingent consideration related to Bioness for the three months ended March 30, 2024 and April 1, 2023 totaled $295 and $287, respectively, and were recorded as the change in fair value of contingent consideration within the consolidated condensed statements of operations and comprehensive loss.
6. Equity-based compensation
2021 Plan
The Company operates an equity-based compensation plan (the “2021 Plan”), which allows for the issuance of stock options (incentive and nonqualified), restricted stock, dividend equivalents, restricted stock units (“RSUs”), other stock-based awards, and cash awards (collectively, the “2021 Plan Awards”). As of March 30, 2024, 19,564,333 shares of Class A common stock have been authorized to be awarded under the 2021 Plan and 9,119,667 shares were available for 2021 Plan Awards.
10

Table of Contents
2023 Plan
The Company also operates the 2023 Retention Equity Award Plan (the “2023 Plan” and, together with the 2021 Plan, the “Plans”), the purpose of which is to retain and motivate critical personnel over the short-term by providing them additional incentives in the form of RSUs (the “Retention Awards” and together with the “2021 Plan Awards,” the “Awards”). As of March 30, 2024, 600,000 shares of Class A common stock were authorized to be awarded under the 2023 Plan and 80,700 shares were available for Retention Awards.
Activity under the Plans
Expense
Equity-based compensation, net for Awards granted under the Plans for the three months ended March 30, 2024 and April 1, 2023 totaled $2,591 and $1,718, respectively. Expenses and expense reductions are primarily included in selling, general and administrative expense with a nominal amount in research and development expense within the consolidated condensed statements of operations and comprehensive loss based upon the department of the employee. There were no income tax benefits related to equity-based compensation expense for the three months ended March 30, 2024. Income tax benefits related to equity-based compensation expense for three months ended April 1, 2023 totaled $430.
Restricted Stock Units
During the three months ended March 30, 2024, the Company granted time-based RSUs which vest at various dates through March 15, 2028. RSU compensation expense is recognized over the vesting period, which is typically between 1 and 4 years. Unamortized compensation expense related to the RSUs totaled $8,159 at March 30, 2024, and is expected to be recognized over a weighted average period of approximately 1.71 years. A summary of the RSU award activity for the three months ended March 30, 2024 is as follows (number of units in thousands):

| Number of units |  | Weighted-average grant-date fair value per unit
Unvested at December 31, 2023 | 2,066 |  |  | $ | 4.51 |
Granted | 2,124 |  |  | 5.34 |
Vested | (196) |  |  | 8.17 |
Forfeited or canceled | (55) |  |  | 8.94 |
Unvested at March 30, 2024 | 3,939 |  |  | $ | 4.69 |

Stock Options
During the three months ended March 30, 2024, the Company granted time-based stock options which vest over 1 to 4 years following the date of grant and expire within 10 years. The fair value of time-based stock options is determined using the Black-Scholes valuation model, with such value recognized as expense over the service period, which is typically 1 to 4 years, net of actual forfeitures. A summary of the Company’s assumptions used in determining the fair value of the stock options granted during the three months ended March 30, 2024 is shown in the following table:

Risk-free interest rate | 3.93% - 4.3%
Expected dividend yield | — | %
Expected stock price volatility | 36.1% - 36.3%
Expected life of stock options (years) | 6.25

The weighted-average grant date fair value of options granted during the three months ended March 30, 2024 was $2.26 per share. The expected term of the options granted is estimated using the simplified method. Expected volatility is based on the historical volatility of the Company’s peers’ common stock. The risk-free interest rate is determined based upon a constant U.S. Treasury security rate with a contractual life that approximates the expected term of the option. Unamortized compensation expense related to the options totaled $5,211 at March 30, 2024, and is expected to be recognized over a weighted average period of approximately 2.15 years.
11

Table of Contents
A summary of stock option activity is as follows for the three months ended March 30, 2024 (number of options in thousands):

| Number of options |  | Weighted-average exercise price |  | Weighted average remaining contractual term |  | Aggregate intrinsic value
Outstanding at December 31, 2023 | 4,347 |  |  | $ | 8.68 |  |  |  |  |
Granted | 1,752 |  |  | 5.18 |  |  |  |  |
Exercised | (209) |  |  | 5.18 |  |  |  |  |
Forfeited or canceled | (332) |  |  | 12.60 |  |  |  |  |
Outstanding at March 30, 2024 | 5,558 |  |  | 7.61 |  |  | 7.39 |  | $ | 3,733 |
Exercisable and vested at March 30, 2024 | 2,149 |  |  | $ | 10.50 |  |  | 4.62 |  | $ | 147 |

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s Class A common stock for options that had exercise prices lower than $5.20 per share as this was the closing price of the Company’s Class A common stock on March 28, 2024, the last trading day of the first quarter.
Employee Stock Purchase Plan
The Company operates a non-qualified Employee Stock Purchase Plan (“ESPP”), which provides for the issuance of shares of the Company’s Class A common stock to eligible employees of the Company that elect to participate in the plan and purchase shares of Class A common stock through payroll deductions at a discounted price. As of March 30, 2024, the aggregate number of shares reserved for issuance under the ESPP was 1,519,604. No shares were issued under the ESPP during the three months ended March 30, 2024. A total of 222,076 shares were issued under the ESPP and $128 of expense was recognized during the three months ended April 1, 2023.
7. Stockholders’ equity
On February 16, 2021, the Company closed an IPO of 9,200,000 shares of Class A common stock through an UP-C structure with BV LLC. In connection with the IPO, the Company amended and restated the limited liability agreement of BV LLC (“BV LLC Agreement”) to provide for a new single class of common membership interests in BV LLC (“LLC Interests”) and exchange all of the existing membership interests in BV LLC (the “Original BV LLC Owners”) for new LLC Interests. The Company also amended its certificate of incorporation to authorize the following shares: (i) 250,000,000 shares of Class A common stock with a par value of $0.001 per share; (ii) 50,000,000 shares of Class B common stock with a par value of $0.001 per share, which have voting rights but no economic interest, and some of which were issued to the Original BV LLC Owners; and (iii) 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company’s board of directors. In connection with the completion of the IPO, the Company acquired, by merger, certain entities that were part of the Original BV LLC Owners (“Former BV LLC Owners”), for which the Company issued 31,838,589 Class A common stock as merger consideration (“IPO Mergers”) and cancelled the Class B common stock held by such Former BV LLC Owners. The IPO Mergers are deemed to be a recapitalization transaction.
Holders of the Company’s Class A and Class B common stock are entitled to one vote per share and, except as otherwise required, will vote together as a single class on all matters on which stockholders generally are entitled to vote. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company. Shares of Class B common stock may only be issued to the extent necessary to maintain the one-to-one ratio between the number of LLC Interests and the number of shares of Class B common stock held by Smith & Nephew, Inc. (the “Continuing LLC Owner”). Shares of Class B common stock are transferable only together with an equal number of LLC Interests. Shares of Class B common stock will be canceled on a one-for-one basis upon the redemption or exchange of any outstanding LLC Interests.
12

Table of Contents
Noncontrolling interest
In connection with any redemption pursuant to the BV LLC Agreement, the Company will receive a corresponding number of LLC Interests, increasing its ownership interest in BV LLC. Future redemptions of LLC Interests will result in a change in ownership and reduce the amount recorded as noncontrolling interest and increase additional paid-in capital. There were no redemptions during the three months ended March 30, 2024 or during the year ended December 31, 2023. The following table summarizes the ownership interest in BV LLC as of March 30, 2024 and December 31, 2023 (number of units in thousands):

| March 30, 2024 |  | December 31, 2023
| LLC Interests |  | Ownership % |  | LLC Interests |  | Ownership %
Number of LLC Interests owned |  |  |  |  |  |  |
Bioventus Inc. | 63,672 |  |  | 80.1 | % |  | 63,267 |  |  | 80.0 | %
Continuing LLC Owner | 15,787 |  |  | 19.9 | % |  | 15,787 |  |  | 20.0 | %
Total | 79,459 |  |  | 100.0 | % |  | 79,054 |  |  | 100.0 | %

8. Earnings per share
The following table sets forth the computation of basic and diluted loss per share of Class A common stock for the periods presented (amounts in thousands, except share and per share data):

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Numerator: |  |  |
Net loss from continuing operations, net of tax | $ | (5,982) |  |  | $ | (100,018) |
Net loss attributable to noncontrolling interests — continuing operations | 1,412 |  |  | 20,360 |
Net loss attributable to Bioventus Inc. Class A common stockholders — continuing operations | $ | (4,570) |  |  | $ | (79,658) |
Numerator: |  |  |
Net loss from discontinued operations, net of tax | $ | — |  |  | $ | (74,429) |
Net loss attributable to noncontrolling interests — discontinued operations | — |  |  | 14,937 |
Net loss attributable to Bioventus Inc. Class A common stockholders — discontinued operations | $ | — |  |  | $ | (59,492) |
Denominator: |  |  |
Weighted-average shares of Class A common stock outstanding - basic and diluted | 63,380,187 |  |  | 62,124,752 |
Net loss per share of Class A common stock from continuing operations, basic and diluted | $ | (0.07) |  |  | $ | (1.28) |
Net loss per share of Class A common stock from discontinued operations, basic and diluted | — |  |  | (0.96) |
Net loss per share of Class A common stock, basic and diluted | $ | (0.07) |  |  | $ | (2.24) |

Shares of Class B common stock do not share in the losses of the Company and are therefore not participating securities. As such, separate presentation of basic and diluted losses per share of Class B common stock under the two-class method has not been presented.
The following number of weighted-average potentially dilutive shares as of March 30, 2024 and April 1, 2023 were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive upon conversion:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
LLC Interests held by Continuing LLC Owner(a) | 15,786,737 |  |  | 15,786,737 |
Stock options | 734,278 |  |  | 8,517,045 |
RSUs | 1,479,188 |  |  | 1,070,105 |
Total | 18,000,203 |  |  | 25,373,887 |

13

Table of Contents
(a)Class A Shares reserved for future issuance upon redemption or exchange of LLC Interests by the Continuing LLC Owner.
9. Restructuring costs
Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. These charges are included in restructuring costs in the consolidated statements of operations and comprehensive loss. Liabilities associated from restructuring costs are recorded in accrued liabilities on the consolidated balance sheets.
The Company’s prior restructuring plans adopted in 2021 and 2022 focused on aligning its organizational and management cost structure to improve profitability and cash flow, reduce headcount and the consolidation of facilities. These plans have been completed. There were no expenses incurred and $840 in restructuring payments for employee severance and temporary labor costs during the three months ended March 30, 2024. Expenses incurred and payments made during the three months ended April 1, 2023 totaled $317 and $1,845, respectively.
10. Income taxes
The tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of its annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. The quarterly tax provision, and estimate of the Company's annual effective tax rate, are subject to variation due to several factors, including variability in pre-tax income (or loss), the mix of jurisdictions to which such income relates, changes in how the Company conducts business, and tax law developments.
For the three months ended March 30, 2024 and April 1, 2023, the Company's effective tax rate was 17.9% and 0.1%, respectively. The change in rate for the three months ended March 30, 2024 compared to the prior year comparable period was primarily due to an increase in taxable income in certain entities.
Tax Receivable Agreement
The Company expects to obtain an increase in the share of the tax basis of the assets of BV LLC when LLC Interests are redeemed or exchanged by the Continuing LLC Owner and other qualifying transactions. This increase in tax basis may have the effect of reducing the amounts that the Company would otherwise pay in the future to various tax authorities. The increase in tax basis may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets.
On February 16, 2021, the Company entered into a tax receivable agreement (“TRA”) with the Continuing LLC Owner that provides for the payment by the Company to the Continuing LLC Owner of 85% of the amount of tax benefits, if any, that the Company actually realizes as a result of (i) increases in the tax basis of assets of BV LLC resulting from any redemptions or exchanges of LLC Interests or any prior sales of interests in BV LLC; and (ii) certain other tax benefits related to our making payments under the TRA.
The Company maintains a full valuation allowance against deferred tax assets related to the tax attributes generated as a result of redemptions of LLC Interests or exchanges described above until it is determined that the benefits are more-likely-than-not to be realized. Subsequent to the consummation of the IPO Mergers, the Continuing LLC Owner has not exchanged LLC Interests for shares of Class A common stock.
11. Commitments and contingencies
Leases
The Company leases its office facilities as well as other property, vehicles and equipment under operating leases. The Company also leases certain office equipment under nominal finance leases. The remaining lease terms range from 1 month to 9.1 years.
14

Table of Contents
The components of lease cost were as follows:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Operating lease cost | $ | 888 |  |  | $ | 1,069 |
Short-term lease cost(a) | 80 |  |  | 206 |
Financing lease cost: |  |  |
Amortization of finance lease assets | 158 |  |  | 235 |
Interest on lease liabilities | 221 |  |  | 137 |
Total lease cost | $ | 1,347 |  |  | $ | 1,647 |

(a)Includes variable lease cost and sublease income, which are immaterial.
Supplemental cash flow information and non-cash activity related to leases were as follows:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Cash paid for amounts included in measurement of lease liabilities: |  |  |
Operating cash flows from operating leases | $ | 1,178 |  |  | $ | 1,100 |
Operating cash flows from financing leases | $ | 221 |  |  | $ | 90 |
Financing cash flows from finance leases | $ | 183 |  |  | $ | 37 |
Right-of-use assets obtained in exchange for lease obligations: |  |  |
Operating lease obligations | $ | 95 |  |  | $ | 225 |
Financing lease obligations | $ | — |  |  | $ | 9,141 |

Supplemental balance sheet and other information related to leases were as follows:

| March 30, 2024 |  | December 31, 2023
Operating lease assets | $ | 12,462 |  | $ | 13,353
Operating lease liabilities—current | $ | 4,028 |  | $ | 4,057
Operating lease liabilities—noncurrent | 9,671 |  | 10,573
Total operating lease liabilities | $ | 13,699 |  | $ | 14,630
Property, plant and equipment, net (finance leases) | $ | 13,884 |  | $ | 14,279
Finance lease liabilities—current | $ | 778 |  | $ | 759
Finance lease liabilities—noncurrent | 10,184 |  | 10,386
Total financing lease liabilities | $ | 10,962 |  | $ | 11,145
Weighted average remaining lease term (years) for leases |  |  |
Operating leases | 3.6 |  | 3.8
Finance leases | 9.1 |  | 9.3
Weighted average discount rate for leases |  |  |
Operating leases | 4.7 | % |  | 4.7 | %
Finance leases | 8.1 | % |  | 8.1 | %

15

Table of Contents
Governmental and legal contingencies
In the normal course of business, the Company periodically becomes involved in various claims and lawsuits, and governmental proceedings and investigations that are incidental to its business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and amount of the claim, and an estimate of the possible loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. With respect to governmental proceedings and investigations, like other companies in the industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries.
The Company is presently unable to predict the duration, scope, or result of these matters. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to these matters. While the Company intends to defend these matters vigorously, the outcome of such litigation or any other litigation is necessarily uncertain, is not within the Company’s complete control and might not be known for extended periods of time. In the opinion of management, the outcome of any existing claims and legal or regulatory proceedings, other than the specific matters described below, if decided adversely, is not expected to have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.
Bioventus shareholder litigation
On January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina, Ciarciello v. Bioventus, Inc., No. 1:23– CV – 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserts violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employees’ Retirement System as lead plaintiff. The plaintiff’s amended consolidated complaint was filed with the Court on June 12, 2023. On July 17, 2023, the defendants filed a motion to dismiss the complaint raising a number of legal and factual deficiencies with the amended consolidated complaint. In response to the defendants’ motion to dismiss, the lead plaintiff filed a second amended complaint on July 31, 2023. The defendants moved to dismiss the second amended complaint on August 21, 2023, which the Court granted in part and denied in part on November 6, 2023. The Court dismissed the plaintiff’s Securities Act claims, but allowed the plaintiff’s Exchange Act claims to proceed into discovery.
On October 4, 2023, certain of the Company’s current and former directors and officers were named as defendants in a derivative shareholder lawsuit (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Grogan, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:23-CV-01099-RGA (D. Del. 2023). The complaint asserts violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On January 12, 2024, the Court agreed to stay this case pending resolution of the Ciarciello case.
On February 9, 2024, another plaintiff filed a derivative shareholder lawsuit against certain of the Company’s current and former directors and officers (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Sanderson, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:24-cv-00180-RGA (D. Del. 2024). Like the Grogan case, this case asserts violations of Section 10(b) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On May 1, 2024, the parties filed a stipulation to consolidate the two derivative matters and stay them on terms similar to those entered in the Grogan case. On May 2, 2024, the United States District Court for the District of Delaware granted the stipulation and ordered the consolidation of the Sanderson and Grogan cases.
The Company believes the claims alleged in each of the above matters lack merit and intends to defend itself vigorously. The outcome of these matters is not presently determinable, and any loss is neither probable nor reasonably estimable.
16

Table of Contents
Misonix former distributor litigation
On March 23, 2017, Misonix’s former distributor in China, Cicel (Beijing) Science & Technology Co., Ltd., filed a lawsuit against Misonix and certain of its officers and directors in the United States District Court for the Eastern District of New York. The complaint alleged that Misonix improperly terminated its contract with the former distributor. The complaint sought various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, and asserted various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. On October 7, 2017, the court granted Misonix’s motion to dismiss each of the tort claims asserted against Misonix, and also granted the individual defendants’ motion to dismiss all claims asserted against them. On January 23, 2020, the court granted Cicel’s motion to amend its complaint, to include claims for alleged defamation and theft of trade secrets in addition to the breach of contract claim. Discovery in the matter ended on August 5, 2021. On January 20, 2022, the court granted Misonix’s summary judgment motion on Cicel’s breach of contract and defamation claims. Cicel’s motion for reconsideration of the court’s summary judgment ruling in Misonix’s favor was dismissed by the Court on April 29, 2022. On July 18, 2022, Cicel voluntarily dismissed the remaining claim for trade secret theft and later filed an appeal to the United States Court of Appeals for the Second Circuit. On March 6, 2024, the Second Circuit Court of Appeals issued its ruling affirming the lower Court’s summary judgment in favor of Misonix in all respects.
Bioness stockholder litigation
On February 8, 2022, a minority shareholder of Bioness filed an action in the Delaware State Court of Chancery in connection with the Company’s acquisition of Bioness, Teuza, a Fairchild Technology Venture Ltd. v. Lindon, et. al., No. 2022-0130 -SG. This action names the former Bioness directors, the Alfred E. Mann Trust (“Trust”), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Company’s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bioness’ and other the defendant’s motions was held before the Court of Chancery on January 19, 2023. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.
Other matters
On November 10, 2021, the Company entered into an asset purchase agreement for an HA product and made an upfront payment of $853. An additional payment of $853 was made in 2022 upon the transfer of certain seller customer data. If the Company is able to obtain a Medical Device Regulation Certification for the product, $1,707 (the “Milestone Payment”) will be paid to the seller within five days. The Company is also required to pay royalties if certifications are achieved before December 31, 2024. Royalties will be payable through 2026 of 5.0% on the first $569 in sales and 2.5% thereafter. On March 8, 2023, the parties amended the agreement under which the Milestone Payment was reduced to $1,418, of which $709 was paid on January 31, 2024, and the remainder is due upon receipt of the Medical Device Regulation Certification for the product provided that it is obtained prior to December 31, 2024. As a result, the Company recorded an intellectual property intangible asset totaling $709 for initial payment.
On August 23, 2019, the Company was assigned a third-party license on a product currently in development and the Company is subject to a 3% royalty on certain commercial sales, or a nominal minimum amount per quarter.
On December 9, 2016, the Company entered into an amended and restated license agreement for the exclusive U.S. distribution and commercialization rights of a single injection osteoarthritis (“OA”) product with the supplier of the Company’s single injection OA product for the non-U.S. market. The agreement requires the Company to meet annual minimum purchase requirements and pay royalties on net sales. Royalties related to this agreement during the three months ended March 30, 2024 and April 1, 2023 totaled $3,579 and $2,321, respectively. These royalties are included in cost of sales within the consolidated condensed statements of operations and comprehensive loss.
As part of a supply agreement entered on February 9, 2016 for the Company’s three injection OA product, the Company is subject to annual minimum purchase requirements for 10 years. After the initial 10 years, the agreement will automatically renew for an additional 5 years unless terminated by the Company or the seller in accordance with the agreement.
As part of a supply agreement for the Company’s five injection OA product that was amended and restated on December 22, 2020, the Company is subject to annual minimum purchase requirements for 8 years.
17

Table of Contents
From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the LOCs reflect the amount of the underlying obligation and are subject to fees payable to the issuers, competitively determined in the marketplace. As of March 30, 2024 and December 31, 2023, the Company had three LOCs outstanding for $1,800.
The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company is self-insured for health insurance covering most of its employees located in the United States. The Company maintains stop-loss insurance on a “claims made” basis for expenses in excess of $250 per member per year.
12. Revenue recognition
Our policies for recognizing sales have not changed from those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated.
As previously discussed in Note 1. Organization, SonicOne revenue was reclassified from Restorative Therapies to Surgical Solutions on a prospective and retrospective basis as its capabilities to remove devitalized or necrotic tissue and fiber deposits more closely aligns with Surgical Solutions’ soft tissue management. SonicOne revenue reclassified for the three months ended April 1, 2023 totaled $1,712 and $65 for the U.S. and International reporting segments, respectively. The Company had product sales to one customer totaling $13,143 in the U.S. segment during the three months ended March 30, 2024, representing 10.2% of total net sales. The following table presents the Company’s net sales disaggregated by major business within each segment as follows:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
U.S. |  |  |
Pain Treatments | $ | 50,637 |  |  | $ | 40,995 |
Restorative Therapies | 25,304 |  |  | 30,776 |
Surgical Solutions | 38,340 |  |  | 32,207 |
Total U.S. net sales | 114,281 |  |  | 103,978 |
International |  |  |
Pain Treatments | 6,052 |  |  | 5,331 |
Restorative Therapies | 5,170 |  |  | 5,549 |
Surgical Solutions | 3,954 |  |  | 4,201 |
Total International net sales | 15,176 |  |  | 15,081 |
Total net sales | $ | 129,457 |  |  | $ | 119,059 |

13. Segments
The Company’s two reportable segments are U.S. and International. U.S. segment revenues totaled $114,281 and $103,978 for the three months ended March 30, 2024 and April 1, 2023, respectively. International segment revenues totaled $15,176 and $15,081 for the three months ended March 30, 2024 and April 1, 2023, respectively. The Company’s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment Adjusted EBITDA is the segment profitability metric reported to the Company’s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.
18

Table of Contents
The following table presents segment Adjusted EBITDA reconciled to loss before income taxes:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Segment Adjusted EBITDA |  |  |
U.S. | $ | 19,756 |  |  | $ | 14,712 |
International | 2,867 |  |  | 2,239 |
Interest expense, net | (10,339) |  |  | (9,694) |
Depreciation and amortization | (11,785) |  |  | (16,473) |
Acquisition and related costs | (211) |  |  | (1,175) |
Shareholder litigation costs | (1,168) |  |  | — |
Restructuring and succession charges | (53) |  |  | (317) |
Equity compensation | (2,591) |  |  | (1,846) |
Financial restructuring costs | (352) |  |  | (5,330) |
Impairments of assets | — |  |  | (78,615) |
Other items | (1,199) |  |  | (3,665) |
Loss before income taxes | $ | (5,075) |  |  | $ | (100,164) |

14. Discontinued operations
On February 27, 2023 the Company reached a Settlement Agreement with the Former Securityholders of CartiHeal that resulted in the transfer of 100% of Company’s shares in CartiHeal to a Trustee. Refer to Note 3. Acquisitions and divestitures for further details concerning the Settlement Agreement and the deconsolidation of CartiHeal. CartiHeal had no sales during the year ended December 31, 2023.
The following table summarizes the major income and expense line items of these discontinued operations, as reported in the consolidated statements of operations for the three months ended April 1, 2023:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Selling, general and administrative expense | $ | — |  |  | $ | 1,728 |
Research and development expense | — |  |  | 396 |
Change in fair value of contingent consideration(a) | — |  |  | 1,710 |
Depreciation and amortization(a) | — |  |  | 4,264 |
Impairments of assets | — |  |  | — |
Operating loss from discontinued operations | — |  |  | 8,098 |
Interest expense, net | — |  |  | 4,889 |
Other (income) expense(b) | — |  |  | 61,442 |
Other (income) expense | — |  |  | 66,331 |
Loss before income taxes | — |  |  | (74,429) |
Income tax benefit, net | — |  |  | — |
Net loss from discontinued operations | — |  |  | (74,429) |
Loss attributable to noncontrolling interest - discontinued operations | — |  |  | 14,937 |
Net loss attributable to Bioventus Inc. - discontinued operations | $ | — |  |  | $ | (59,492) |

(a)Depreciation and amortization and the change in fair value of contingent consideration represents the significant operating non-cash items of discontinued operations.
(b)Other expense includes the $60,639 loss on deconsolidation, of which $10,150 was attributable to non-refundable payments. Total investing cash outflows included these non-refundable payments and $1,356 cash on hand at disposal.
19

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of Bioventus Inc.’s (sometimes referred to as “we,” “us,” “our,” “Bioventus” or “the Company”) financial condition and results of operations should be read in conjunction with the “Special Note Regarding Forward-Looking Statements” and our unaudited consolidated condensed financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on March 12, 2024 (“2023 10-K”).
Executive Summary
We are a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing process. We operate our business through two reportable segments, U.S. and International, and our portfolio of products is grouped into three businesses:
•Pain Treatments is comprised of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (“PNS”) products to help the patient get back to their normal activities.
•Surgical Solutions is comprised of bone graft substitutes (“BGS”) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management (i.e., tumor and liver resections) and tissue debridement, in various surgeries, including minimally invasive applications.
•Restorative Therapies is comprised of a bone healing system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
The following table sets forth total net sales, net loss and Adjusted EBITDA for the periods presented:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Net sales | $ | 129,457 |  |  | $ | 119,059 |
Net loss from continuing operations | $ | (5,982) |  |  | $ | (100,018) |
Adjusted EBITDA(1) | $ | 22,623 |  |  | $ | 16,951 |
Loss per Class A common stock, basic and diluted: |  |  |
Continuing operations | $ | (0.07) |  |  | $ | (1.28) |
Discontinued operations | — |  |  | (0.96) |
Loss per Class A common stock, basic and diluted | $ | (0.07) |  |  | $ | (2.24) |

(1)See below under results of operations-Adjusted EBITDA for a reconciliation of net loss to Adjusted EBITDA.
Significant transactions
Reclassification
We reclassified revenue and expense of the SonicOne Ultrasonic Cleansing and Debridement Systems (“SonicOne”) from the Restorative Therapies to the Surgical Solutions business in 2024. SonicOne’s capabilities to remove devitalized or necrotic tissue and fiber deposits more closely aligns with Surgical Solutions’ soft tissue management. SonicOne revenue reclassified for the three months ended April 1, 2023 totaled $1,712 and $65 for the U.S. and International reporting segments, respectively.
EU MDR
The European Union (“EU”) Medical Devices Regulation (“MDR”), which became effective in May 2021, was adopted with the aim of ensuring better protection of public health and patient safety. Among other things, the EU MDR imposed changes to clinical evidence for medical devices, post-market clinical follow-up evidence, annual reporting of safety information for Class III products, and bi-annual reporting for Class II products, Unique Device Identification (“UDI”) for all products, submission of core data elements to a European UDI database prior to placement of a device on the market, reclassification of medical devices, and multiple labeling changes. We were able to continue marketing our currently certified products in the EU after the effective date of EU MDR until the associated certifications expire. In April 2024, we received EU Certification for our Exogen Bone Stimulation System, which will allow us to market it throughout the EU. The certificate is valid for 5 years.
20

Table of Contents
Wound Business
On May 22, 2023, we closed the sale of certain assets within our Wound Business, including the TheraSkin and TheraGenesis products (collectively, the “Wound Business” or the “Disposal Group”), for potential consideration of $84.7 million, including $34.7 million at closing, $5.0 million deferred for 18 months and up to $45.0 million in potential earn-out payments (“Earn-out Payments”), which are based on the achievement of certain revenue thresholds by the purchaser of the Wound Business for sales of the TheraSkin and TheraGenesis products during the 2024, 2025, and 2026 fiscal years. We incurred $3.9 million in transactional fees resulting from the sale of the Wound Business and used the proceeds from the sale of the Wound Business to prepay $30.0 million of long-term debt obligations.
We evaluated the Wound Business for impairment prior to its sale and recorded a $78.6 million impairment within the consolidated statements of operations and comprehensive loss during the three months ended April 1, 2023 as a result of this evaluation to reduce the intangible assets of the Disposal Group to reflect their respective fair values, less any costs to sell. The fair value of the Disposal Group’s intangibles were determined based on the consideration received for the Wound Business.
Amended 2019 Credit Agreement
On January 18, 2024, we further amended the 2019 Credit Agreement in order to modify certain financial covenants under the 2019 Credit Agreement. Refer to Part I. Item 1. Financial Information—Notes to the consolidated condensed financial statements—Note 4. Financial instruments for further information regarding the January 2024 amendment.
Consolidated Appropriations Act
In July 2022, in connection with the Consolidated Appropriations Act, 2021 (“CAA”), the Centers for Medicare and Medicaid Services (“CMS”) began utilizing new pricing information the Company reported to it pursuant to the newly adopted reporting obligations to adjust the Medicare payment to healthcare providers using our Durolane and Gelsyn-3 products.
Results of Operations
For a description of the components of our results of operations, refer to Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2023 10-K.
The following table sets forth components of our consolidated condensed statements of operations as a percentage of net sales for the periods presented:

| Three Months Ended
| March 30, 2024 |  | April 1, 2023
Net sales | 100.0 | % |  | 100.0 | %
Cost of sales (including depreciation and amortization) | 31.7 | % |  | 37.9 | %
Gross profit | 68.3 | % |  | 62.1 | %
Selling, general and administrative expense | 60.6 | % |  | 67.9 | %
Research and development expense | 2.0 | % |  | 3.2 | %
Restructuring costs | — | % |  | 0.3 | %
Change in fair value of contingent consideration | 0.2 | % |  | 0.2 | %
Depreciation and amortization | 1.4 | % |  | 1.8 | %
Impairment of assets | — | % |  | 66.0 | %
Operating income (loss) | 4.1 | % |  | (77.3 | %)

21

Table of Contents
The following table presents a reconciliation of net loss to Adjusted EBITDA for the periods presented:

| Three Months Ended
(in thousands) | March 30, 2024 |  | April 1, 2023
Net loss from continuing operations | $ | (5,982) |  |  | $ | (100,018) |
Interest expense, net | 10,339 |  |  | 9,694 |
Income tax expense (benefit), net | 907 |  |  | (146) |
Depreciation and amortization(a) | 11,785 |  |  | 16,473 |
Acquisition and related costs(b) | 211 |  |  | 1,175 |
Shareholder litigation costs(c) | 1,168 |  |  | — |
Restructuring and succession charges(d) | 53 |  |  | 317 |
Equity compensation(e) | 2,591 |  |  | 1,846 |
Financial restructuring costs(f) | 352 |  |  | 5,330 |
Impairment of assets(g) | — |  |  | 78,615 |
Other items(h) | 1,199 |  |  | 3,665 |
Adjusted EBITDA | $ | 22,623 |  |  | $ | 16,951 |

(a)Includes for the three months ended March 30, 2024 and April 1, 2023, respectively, depreciation and amortization of $10,025 and $14,339 in cost of sales and $1,760 and $2,134 in operating expenses presented in the consolidated condensed statements of operations and comprehensive loss.
(b)Includes acquisition and integration costs related to completed acquisitions and changes in fair value of contingent consideration.
(c)Costs incurred as a result of certain shareholder litigation unrelated to our ongoing operations.
(d)Costs incurred were the result of adopting restructuring plans to reduce headcount, reorganize management structure, and consolidate certain facilities.
(e)Includes compensation expense resulting from awards granted under our equity-based compensation plans.
(f)Financial restructuring costs include advisory fees and debt amendment related costs.
(g)Represents a non-cash impairment charge for intangible assets attributable to our Wound Business due to our decision to divest the business.
(h)Other items primarily includes charges associated with strategic transactions, such as potential acquisitions or divestitures and a transformative project to redesign systems and information processing.
Non-GAAP Financial Measures - Adjusted EBITDA
We present Adjusted EBITDA, a non-GAAP financial measure, because we believe it is a useful indicator that management uses as a measure of operating performance as well as for planning purposes, including the preparation of our annual operating budget and financial projections. We believe that Adjusted EBITDA is useful to our investors because it is frequently used by securities analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to ours. We define Adjusted EBITDA as net loss from continuing operations before depreciation and amortization, provision of income taxes and interest expense, net, adjusted for the impact of certain cash, non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include acquisition and related costs, certain shareholder litigation costs, impairments of assets, restructuring and succession charges, equity compensation expense, financial restructuring costs and other items. We included certain shareholder litigation costs as a new item within our Adjusted EBITDA calculation during the first quarter of 2024 as it was the first period in which costs related to this type of litigation were material to our business. Costs related to this shareholder litigation are unrelated to our ongoing operations and were nominal in prior periods. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs primarily based on a ratio of net sales by segment to total consolidated net sales.
Non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. These measures might exclude certain normal recurring expenses. Therefore, these measures might not provide a complete understanding of the Company's performance and should be reviewed in conjunction with the U.S. GAAP financial measures. Additionally, other companies might define their non-GAAP financial measures differently than we do. Investors are encouraged to review the reconciliation of the non-GAAP measure provided in this Quarterly Report on Form 10-Q, including all tables referencing Adjusted EBITDA to its most directly comparable U.S. GAAP measure.
22

Table of Contents
Net Sales

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
U.S. |  |  |  |  |  |  |
Pain Treatments | $ | 50,637 |  |  | $ | 40,995 |  |  | $ | 9,642 |  |  | 23.5 | %
Restorative Therapies | 25,304 |  |  | 30,776 |  |  | (5,472) |  |  | (17.8 | %)
Surgical Solutions | 38,340 |  |  | 32,207 |  |  | 6,133 |  |  | 19.0 | %
Total U.S. net sales | 114,281 |  |  | 103,978 |  |  | 10,303 |  |  | 9.9 | %
International |  |  |  |  |  |  |
Pain Treatments | 6,052 |  |  | 5,331 |  |  | 721 |  |  | 13.5 | %
Restorative Therapies | 5,170 |  |  | 5,549 |  |  | (379) |  |  | (6.8 | %)
Surgical Solutions | 3,954 |  |  | 4,201 |  |  | (247) |  |  | (5.9 | %)
Total International net sales | 15,176 |  |  | 15,081 |  |  | 95 |  |  | 0.6 | %
Total net sales | $ | 129,457 |  |  | $ | 119,059 |  |  | $ | 10,398 |  |  | 8.7 | %

U.S.
Net sales increased $10.3 million, or 9.9%, compared to the prior year period. Changes by business were: (i) Pain Treatments—$9.6 million increase due to volume; (ii) Restorative Therapies—$5.5 million decrease due to the divestiture of our Wound Business, partially offset with a volume increase for our Exogen Bone Stimulation System; and (iii) Surgical Solutions—$6.1 million increase due to volume growth.
International
Net sales remained consistent with the prior year comparable period.
Gross profit and gross margin

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
U.S. | $ | 79,368 |  |  | $ | 65,506 |  |  | $ | 13,862 |  |  | 21.2 | %
International | 9,012 |  |  | 8,413 |  |  | 599 |  |  | 7.1 | %
Total | $ | 88,380 |  |  | $ | 73,919 |  |  | $ | 14,461 |  |  | 19.6 | %

| Three Months Ended
| March 30, 2024 |  | April 1, 2023 |  | Change
U.S. | 69.4 | % |  | 63.0 | % |  | 6.4 | %
International | 59.4 | % |  | 55.8 | % |  | 3.6 | %
Total | 68.3 | % |  | 62.1 | % |  | 6.2 | %

U.S.
Gross profit increased $13.9 million, or 21.2%, primarily due to volume growth in Pain Treatments, Surgical Solutions and our Exogen Bone Stimulation System, partially offset by the Wound Business divestiture. Gross margin increased due to product mix.
International
Gross profit increased $0.6 million, or 7.1%, primarily due to volume growth in Pain Treatments. Gross margin increased due to product mix.
Selling, general and administrative expense

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Selling, general and administrative expense | $ | 78,406 |  |  | $ | 80,858 |  |  | $ | (2,452) |  |  | (3.0 | %)

23

Table of Contents
Selling, general and administrative expenses decreased $2.5 million, or 3.0%, primarily due to a decline in consulting expenses of $7.0 million and bad debt of $2.1 million. These decreases were partially offset with increases in: (i) compensation-related costs of $4.3 million; (ii) equity-based compensation costs of $1.3 million; and (iii) corporate and employee health insurance of $1.0 million.
Research and development expense

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Research and development expense | $ | 2,597 |  |  | $ | 3,771 |  |  | $ | (1,174) |  |  | (31.1 | %)

Research and development expense decreased by $1.2 million, or 31.1%, primarily due to a decrease of $0.7 million in consulting costs and $0.6 million in equity-based compensation.
Restructuring costs

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Restructuring costs | $ | — |  |  | $ | 317 |  |  | $ | (317) |  |  | (100.0 | %)

The Company’s previously announced restructuring plans were completed in 2023. Costs incurred during the first quarter of 2023 is primarily the result of an initiative to align the Company’s organizational and management cost structure to improve profitability and cash flow through headcount reduction and cutting third-party related costs.
Change in fair value of contingent consideration

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Change in fair value of contingent consideration | $ | 295 |  |  | $ | 287 |  |  | $ | 8 |  |  | 2.8 | %

The fair value of contingent consideration during the three months ended March 30, 2024 remained consistent with the prior year comparable period. The activity for both periods relates to contingent consideration associated with the acquisition of Bioness in March 2021.
Depreciation and amortization

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Depreciation and amortization | $ | 1,755 |  |  | $ | 2,129 |  |  | $ | (374) |  |  | (17.6 | %)

Depreciation and amortization decreased during the three months ended March 30, 2024 compared with the prior year comparable period. The decrease was primarily the result of the impairment of intellectual property intangible assets associated with the Wound Business, which was divested during the second quarter of 2023.
Impairment of assets
Our decision to divest the Wound Business required us to evaluate whether certain of its assets were impaired. We recorded a $78.6 million non-cash impairment charge as a result of this evaluation to reduce the intangible assets to their fair values less costs to sell. The fair value of intangibles of the Wound Business was determined based on the consideration offered for the Wound Business.
Other expense (income)

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Interest expense, net | $ | 10,339 |  |  | $ | 9,694 |  |  | $ | 645 |  |  | 6.7 | %
Other expense (income) | $ | 63 |  |  | $ | (1,588) |  |  | $ | 1,651 |  |  | (104.0 | %)

Interest expense, net increased $0.6 million due to slightly higher interest rates partially offset with a decrease in outstanding debt. Other expense (income) decreased $1.7 million due to the 2023 receipt of $1.5 million from the settlement of a legal claim.
24

Table of Contents
Income tax expense (benefit), net

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Income tax expense (benefit), net | $ | 907 |  |  | $ | (146) |  |  | $ | 1,053 |  |  | NM
Effective tax rate (NM = Not Meaningful) | 17.9 | % |  | 0.1 | % |  |  |  | 17.7 | %

Income tax expense was incurred for the three months ended March 30, 2024 compared to a benefit in the prior year comparable period primarily due to an increase in taxable income in certain entities.
Noncontrolling interest
Subsequent to the IPO and related transactions, we are the sole managing member of BV LLC in which we owned 80.1% and 79.9% at March 30, 2024 and December 31 2023, respectively. We have a majority economic interest, the sole voting interest in, and control the management of BV LLC. As a result, we consolidate the financial results of BV LLC and report a noncontrolling interest representing the 19.9% that is owned by the Continuing LLC Owner. Noncontrolling interest activity during the three months ended March 30, 2024 was the result of losses recorded.
Segment Adjusted EBITDA

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
U.S. | $ | 19,756 |  |  | $ | 14,712 |  |  | $ | 5,044 |  |  | 34.3 | %
International | $ | 2,867 |  |  | $ | 2,239 |  |  | $ | 628 |  |  | 28.0 | %

U.S.
Adjusted EBITDA increased $5.0 million, or 34.3%, primarily due higher gross profit, partially offset with an increase in compensation costs and other administrative expenses.
International
Adjusted EBITDA increased $0.6 million, or 28.0%, primarily due to the increase in gross profit.
Liquidity and Capital Resources
Sources of liquidity
Our principal liquidity needs have historically been for acquisitions, working capital, research and development, clinical trials, and capital expenditures. We expect these needs to continue as we carry out our operations, develop and commercialize our existing product candidates and any new products candidates and possibly further our expansion into international markets.
As previously discussed, on May 22, 2023, we closed the sale of our Wound Business for consideration of $84.7 million, including $34.7 million at closing, $5.0 million deferred for 18 months and up to $45.0 million in potential earn-out payments. The proceeds were used to prepay $30.0 million of long-term debt principal obligations during the second quarter of 2023.
We anticipate that to the extent that we require additional liquidity, we will obtain funding through additional equity financings or the incurrence of other indebtedness or a combination of these potential sources of liquidity. We may explore additional divestiture opportunities for non-core assets to improve our liquidity position, as we did with the Wound Business. In addition, we may raise additional funds to finance future cash needs through receivables or royalty financings or corporate collaboration and licensing arrangements. If we raise additional funds by issuing equity securities or convertible debt, our stockholders will experience dilution. The covenants under the Amended 2019 Credit Agreement limit our ability to obtain additional debt financing. Debt financing, if allowed under the Amended 2019 Credit Agreement and if available, would result in increased payment obligations and might involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, or making capital expenditures. If we raise additional funds through collaboration and licensing arrangements with third-parties, it might be necessary to relinquish valuable rights to our products, future revenue streams or product candidates, or to grant licenses on terms that might not be favorable to us. We cannot be certain that additional funding will be available on acceptable terms, or at all.
25

Table of Contents
Any failure to raise capital in the future might have a negative impact on our financial condition and our ability to pursue our business strategies. Considering recent market conditions and our business assumptions, we have reevaluated our operating cash flows and cash requirements and believe that current cash, cash equivalents, future cash flows from operating activities and cash available under our 2019 Credit Facility will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the unaudited consolidated condensed financial statements included herein.
Cash Requirements
There have been no material changes to our future cash requirements as disclosed in Part II. Item 7 of our 2023 10-K.
We enter into contracts in the normal course of business with various third parties for development, collaboration and other services for operating purposes. These contracts generally provide for termination upon notice. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. Certain agreements include contingent events that upon occurrence would require payment. For information regarding commitments and contingencies, refer to Item 1. Financial Information—Notes to the unaudited consolidated condensed financial statements—Note 11. Commitments and contingencies.
Tax Receivable Agreement
The BV LLC Agreement provides for the payment of certain distributions to the Continuing LLC Owner in amounts sufficient to cover the income taxes imposed with respect to the allocation of taxable income from BV LLC as well as obligations within the tax receivable agreement (“TRA”) with the Continuing LLC Owner. Under the TRA, we are required to make cash payments to the Continuing LLC Owner equal to 85% of the tax benefits, if any, that we actually realize (or in certain circumstances are deemed to realize), as a result of (1) increases in the tax basis of assets of BV LLC resulting from (a) any future redemptions or exchanges of LLC Interests, and (b) certain distributions (or deemed distributions) by BV LLC and (2) certain other tax benefits arising from payments under the TRA. We expect the amount of the cash payments required to be made under the TRA will be significant. The actual amount and timing of any payments under the TRA will vary depending upon a number of factors, including the timing of redemptions or exchanges by the Continuing LLC Owner, the amount of gain recognized by the Continuing LLC Owner, the amount and timing of the taxable income we generate in the future, and the federal tax rates then applicable. Any payments made by us to the Continuing LLC Owner under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we are unable to make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA.
Indebtedness
On January 18, 2024 (the “Closing Date”), the Company entered into the Amended 2019 Credit Agreement. The Amended 2019 Credit Agreement, contains customary affirmative and negative covenants, including those related to financial reporting and notification, restrictions on the declaration or payment of certain distributions on or in respect of our equity interests, restrictions on acquisitions, investments and certain other payments, limitations on the incurrence of new indebtedness, limitations on transfers, sales and other dispositions of our assets, as well as limitations on making changes to the business and organizational documents. Financial covenant requirements include a maximum debt leverage ratio and an interest coverage ratio. In addition, during the period commencing on the Closing Date and ending upon the satisfaction of certain conditions occurring not prior to the delivery of our financial statements for the fiscal quarter ending October 29, 2025, we will be subject to certain additional requirements and covenants, including a requirement to maintain Liquidity (as defined in the Amended 2019 Credit Agreement) of not less than $10.0 million as of the end of each calendar month during such period. The Term Loan Facilities will mature on October 29, 2026. The Revolver will mature on October 29, 2025. We were in compliance with the financial covenants as stated with the Amended 2019 Credit Agreement as of March 30, 2024.
We have an outstanding Revolver balance of $15.0 million as of March 30, 2024, which was borrowed and used for working capital needs during the third quarter of 2023.
Refer to Item 1. Financial Information—Notes unaudited consolidated condensed financial statements—Note 1. Organization for further details on the Company’s covenant compliance and Note 4. Financial instruments for further details on the Company’s indebtedness.
Other
For information regarding Commitments and Contingencies, refer to Item 1. Financial Information—Notes to the unaudited consolidated condensed financial statements—Note 11. Commitments and contingencies and —Note 3. Acquisitions and divestitures of this Quarterly Report on Form 10-Q.
26

Table of Contents
Information regarding cash flows
Cash, cash equivalents and restricted cash as of March 30, 2024 totaled $25.2 million, compared to $37.0 million as of December 31, 2023. The decrease in cash was primarily due to the following:

| Three Months Ended |  | Change
(in thousands, except for percentage) | March 30, 2024 |  | April 1, 2023 |  | $ |  | %
Cash flows from continuing operations: |  |  |  |  |  |  |
Net cash from operating activities | $ | (6,005) |  |  | $ | 4,659 |  |  | $ | (10,664) |  |  | (228.9 | %)
Net cash from investing activities | (1,000) |  |  | (3,560) |  |  | 2,560 |  |  | (71.9 | %)
Net cash from financing activities | (4,242) |  |  | 27,380 |  |  | (31,622) |  |  | (115.5 | %)
Net cash from discontinued operations | — |  |  | (13,675) |  |  | 13,675 |  |  | (100.0 | %)
Effect of exchange rate changes on cash | (544) |  |  | 461 |  |  | (1,005) |  |  | (218.0 | %)
Net change in cash, cash equivalents and restricted cash | $ | (11,791) |  |  | $ | 15,265 |  |  | $ | (27,056) |  |  | (177.2 | %)

NM = Not Meaningful
Operating Activities
Net cash from operating activities from continuing operations decreased $10.7 million, due to: (i) increases in employee compensation as we annually pay bonuses and raise wages during the first quarter and no bonuses were paid during the first quarter of 2023; (ii) a rise in interest payments due to higher interest rates; and (iii) an increase in inventory purchases. These operating cash outflows were partially offset with an increase in cash collections from the growth in sales and timing of payments on accounts payable.
Investing Activities
Net cash from investing activities from continuing operations increased $2.6 million, due to a decrease of $3.3 million in capital expenditures, primarily within information technology. This was partially offset with $0.7 million purchase of distribution rights for one of our HA products.
Financing Activities
Cash flows from financing activities decreased $31.6 million, primarily due to no new borrowings in 2024 on our revolving credit facility compared to $29.0 million in net borrowings during 2023 and an increase of $3.1 million in debt principal payments.
Discontinued Operations
Net cash flows from discontinued operations in 2023 were primarily the result of $10.2 million in fees used to settle the CartiHeal disposition and $1.4 million in cash held by the CartiHeal entity at the time of disposal.
Off-balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Contractual Obligations
There have been no material changes to our contractual obligations as disclosed in our 2023 10-K.
Critical Accounting Estimates
Our discussion of operating results is based upon the unaudited consolidated condensed financial statements and accompanying notes, which have been prepared in accordance with U.S. GAAP. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our estimates are based on our historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates. In the event we dispose of assets before the end of their previously stated useful life, we may incur an impairment charge. Our critical accounting estimates are detailed in Item 7 of our 2023 10-K and we have no material changes to such disclosures.
Recently Issued Accounting Pronouncements
There were no recently issued accounting pronouncements that are expected to materially impact our financial statements.
27

Table of Contents
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
There have been no material changes to our market risks as disclosed in our 2023 10-K.
Item 4. Controls and Procedures.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Our management, including our President and Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated under the Exchange Act) as of March 30, 2024 (the end of the period covered by this Quarterly Report on Form 10-Q). Based upon that evaluation, our President and Chief Executive Officer and Chief Financial Officer concluded that, as of March 30, 2024, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the first quarter of 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
Bioventus stockholder litigation
On January 12, 2023, the Company and certain of its current and former directors and officers were named as defendants in a putative class action lawsuit filed in the Middle District of North Carolina, Ciarciello v. Bioventus, Inc., No. 1:23– CV – 00032-CCE-JEP (M.D.N.C. 2023). The complaint asserts violations of Sections 10(b) and 20(a) of the Exchange Act and of Sections 11 and 15 of the Securities Act and generally alleges that the Company failed to disclose certain information regarding rebate practices, its business and financial prospects, and the sufficiency of internal controls regarding financial reporting. The complaint seeks damages in an unspecified amount. On April 12, 2023, the Court appointed Wayne County Employees’ Retirement System as lead plaintiff. The plaintiff’s amended consolidated complaint was filed with the Court on June 12, 2023. On July 17, 2023, the defendants filed a motion to dismiss the complaint raising a number of legal and factual deficiencies with the amended consolidated complaint. In response to the defendants’ motion to dismiss, the lead plaintiff filed a second amended complaint on July 31, 2023. The defendants moved to dismiss the second amended complaint on August 21, 2023, which the Court granted in part and denied in part on November 6, 2023. The Court dismissed the plaintiff’s Securities Act claims, but allowed the plaintiff’s Exchange Act claims to proceed into discovery.
On October 4, 2023, certain of the Company’s current and former directors and officers were named as defendants in a derivative shareholder lawsuit (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Grogan, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:23-CV-01099-RGA (D. Del. 2023). The complaint asserts violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On January 12, 2024, the Court agreed to stay this case pending resolution of the Ciarciello case.
28

Table of Contents
On February 9, 2024, another plaintiff filed a derivative shareholder lawsuit against certain of the Company’s current and former directors and officers (in which the Company is a nominal defendant) filed in the United States District Court for the District of Delaware, Sanderson, on behalf of Bioventus Inc., v. Reali, et.al., No. 1:24-cv-00180-RGA (D. Del. 2024). Like the Grogan case, this case asserts violations of Section 10(b) of the Exchange Act, breaches of fiduciary duties and related state law claims, and a claim for contribution, and generally alleges the same purported misconduct as alleged in the Ciarciello case. On May 1, 2024, the parties filed a stipulation to consolidate the two derivative matters and stay them on terms similar to those entered in the Grogan case. On May 2, 2024, the United States District Court for the District of Delaware granted the stipulation and ordered the consolidation of the Sanderson and Grogan cases.
The Company believes the claims alleged in each of the above matters lack merit and intends to defend itself vigorously. The outcome of these matters is not presently determinable, and any loss is neither probable nor reasonably estimable.
Misonix former distributor litigation
On March 23, 2017, Misonix’s former distributor in China, Cicel (Beijing) Science & Technology Co., Ltd., filed a lawsuit against Misonix and certain of its officers and directors in the United States District Court for the Eastern District of New York. The complaint alleged that Misonix improperly terminated its contract with the former distributor. The complaint sought various remedies, including compensatory and punitive damages, specific performance and preliminary and post judgment injunctive relief, and asserted various causes of action, including breach of contract, unfair competition, tortious interference with contract, fraudulent inducement, and conversion. On October 7, 2017, the court granted Misonix’s motion to dismiss each of the tort claims asserted against Misonix, and also granted the individual defendants’ motion to dismiss all claims asserted against them. On January 23, 2020, the court granted Cicel’s motion to amend its complaint, to include claims for alleged defamation and theft of trade secrets in addition to the breach of contract claim. Discovery in the matter ended on August 5, 2021. On January 20, 2022, the court granted Misonix’s summary judgment motion on Cicel’s breach of contract and defamation claims. Cicel’s motion for reconsideration of the court’s summary judgment ruling in Misonix’s favor was dismissed by the Court on April 29, 2022. On July 18, 2022, Cicel voluntarily dismissed the remaining claim for trade secret theft and later filed an appeal to the United States Court of Appeals for the Second Circuit. On March 6, 2024, the Second Circuit Court of Appeals issued its ruling affirming the lower Court’s summary judgment in favor of Misonix in all respects.
Bioness stockholder litigation
On February 8, 2022, a minority shareholder of Bioness filed an action in the Delaware State Court of Chancery in connection with the Company’s acquisition of Bioness, Teuza, a Fairchild Technology Venture Ltd. v. Lindon, et. al., No. 2022-0130 -SG. This action names the former Bioness directors, the Alfred E. Mann Trust (“Trust”), which was the former majority shareholder of Bioness, the trustees of the Trust and Bioventus as defendants. The complaint alleges, among other things, that the individual directors, the Trust, and the trustees breached their fiduciary duty to the plaintiff in connection with their consideration and approval of the Company’s transaction. The complaint also alleges that the Company aided and abetted the other defendants in breaching their fiduciary duties to the plaintiff and that the Company breached the Merger Agreement by failing to pay the plaintiff its pro rata share of the merger consideration. The Company believes that it is indemnified under the indemnification provisions contained in the Bioness Merger Agreement for these claims. On July 20, 2022, the Company filed a motion to dismiss all claims made against it on various grounds, as did all the other named defendants in the suit. A hearing on Bioness’ and other the defendant’s motions was held before the Court of Chancery on January 19, 2023. On April 27, 2023, the Court issued an order which, among other things, dismissed Bioventus from the case.
Please refer to Item 1. Financial Statements—Notes to the Consolidated Condensed Financial Statements—Note 11. Commitments and contingencies of this Quarterly Report on Form 10-Q for additional information pertaining to legal proceedings. In addition, we are party to legal proceedings incidental to our business. While our management currently believes the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on our consolidated financial statements, litigation is subject to inherent uncertainties. Were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on our financial condition and results of operations.
Item 1A. Risk Factors.
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described under the heading Risk Factors included in our 2023 10-K, which could materially affect our businesses, financial condition, or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, or future results. There have been no material changes in our risk factors from those described in our 2023 Form 10-K.
29

Table of Contents
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.
(a)None.
(b)None.
(c)None.
Item 3. Defaults Upon Senior Securities.
Not Applicable.
Item 4. Mine Safety Disclosures.
Not Applicable.
Item 5. Other Information.
Insider Trading Arrangements
On January 11, 2024, our President and Chief Executive Officer, Robert E. Claypoole made an election to sell shares of Company Class A common stock to cover withholding taxes that may become due pursuant to the vesting of RSUs granted to Mr. Claypoole effective that same day. On March 15, 2024, our Chief Financial Officer (Mark L. Singleton), Senior Vice President and General Counsel (Anthony D’Adamio) and Senior Vice President and Chief Compliance Officer (Katrina Church) each made an election to sell shares of Company Class A common stock to cover withholding taxes that may become due pursuant to the vesting of RSUs granted to such officers effective that same day. Each of the aforementioned elections are designed to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Item 6. Exhibits.

Exhibit No. |  | Description |  | Form |  | File No. |  | Exhibit |  | Filing Date | ` | Filed / Furnished Herewith
10.1 |  | Amendment No. 5 to Credit and Guaranty Agreement between Bioventus LLC, Guarantor Subsidiaries party thereto, Wells Fargo Bank, National Association, as administrative agent and collateral agent, and the lenders and other financial institutions party thereto, dated January 18, 2024 |  | 8-K |  | 001-37844 |  | 10.1 |  | 1/19/2024 |  |
31.1 |  | Certification of President and Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended |  |  |  |  |  |  |  |  |  | *
31.2 |  | Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended |  |  |  |  |  |  |  |  |  | *
32 |  | Certification of President and Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |  |  | **
101.INS |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |  |  |  |  |  |  |  |  |  | ***
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |  |  |  |  |  | ***
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |  |  |  |  |  | ***

Table of Contents

Exhibit No. |  | Description |  | Form |  | File No. |  | Exhibit |  | Filing Date | ` | Filed / Furnished Herewith
101.DEF |  | Inline XBRL Extension Definition Linkbase Document |  |  |  |  |  |  |  |  |  | ***
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  |  |  |  |  |  | ***
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |  |  |  |  |  | ***
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |  |  |  |  |  |  |  |  |  | *

* Filed herewith
** Furnished herewith
*** Submitted electronically herewith
31

Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.

|  | BIOVENTUS INC.
May 7, 2024 |  | /s/ Mark L. Singleton
Date |  | Mark L. Singleton
|  | Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

32